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A B S T R A C T
Background
Down’s syndrome occurs when a person has three copies of chromosome 21, or the specific area of chromosome 21 implicated in causing
Down’s syndrome, rather than two. It is the commonest congenital cause of mental disability and also leads to numerous metabolic and
structural problems. It can be life-threatening, or lead to considerable ill health, although some individuals have only mild problems
and can lead relatively normal lives. Having a baby with Down’s syndrome is likely to have a significant impact on family life. The risk
of a Down’s syndrome affected pregnancy increases with advancing maternal age.
Noninvasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates
of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing. Before agreeing to
screening tests, parents need to be fully informed about the risks, benefits and possible consequences of such a test. This includes
subsequent choices for further tests they may face, and the implications of both false positive and false negative screening tests (i.e.
invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal). The decisions that may be faced
by expectant parents inevitably engender a high level of anxiety at all stages of the screening process, and the outcomes of screening can
be associated with considerable physical and psychological morbidity. No screening test can predict the severity of problems a person
with Down’s syndrome will have.
Objectives
To estimate and compare the accuracy of first and second trimester urine markers for the detection of Down’s syndrome.
Search methods
We carried out a sensitive and comprehensive literature search of MEDLINE (1980 to 25 August 2011), EMBASE (1980 to 25 August
2011), BIOSIS via EDINA (1985 to 25 August 2011), CINAHL via OVID (1982 to 25 August 2011), The Database of Abstracts of
Reviews of Effectiveness (The Cochrane Library 2011, Issue 7), MEDION (25 August 2011), The Database of Systematic Reviews and
Meta-Analyses in Laboratory Medicine (25 August 2011), The National Research Register (archived 2007), Health Services Research
Projects in Progress database (25 August 2011). We studied reference lists and published review articles.
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Selection criteria
Studies evaluating tests of maternal urine in women up to 24 weeks of gestation for Down’s syndrome, compared with a reference
standard, either chromosomal verification or macroscopic postnatal inspection.
Data collection and analysis
We extracted data as test positive or test negative results for Down’s and non-Down’s pregnancies allowing estimation of detection rates
(sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS (Quality Assessment of
Diagnostic Accuracy Studies) criteria. We used hierarchical summary ROC (receiver operating characteristic) meta-analytical methods
to analyse test performance and compare test accuracy. We performed analysis of studies allowing direct comparison between tests. We
investigated the impact of maternal age on test performance in subgroup analyses.
Main results
We included 19 studies involving 18,013 pregnancies (including 527 with Down’s syndrome). Studies were generally of high quality,
although differential verification was common with invasive testing of only high-risk pregnancies. Twenty-four test combinations
were evaluated formed from combinations of the following seven different markers with and without maternal age: AFP (alpha-
fetoprotein), ITA (invasive trophoblast antigen), ß-core fragment, free ßhCG (beta human chorionic gonadotrophin), total hCG,
oestriol, gonadotropin peptide and various marker ratios. The strategies evaluated included three double tests and seven single tests in
combination with maternal age, and one triple test, two double tests and 11 single tests without maternal age. Twelve of the 19 studies
only evaluated the performance of a single test strategy while the remaining seven evaluated at least two test strategies. Two marker
combinations were evaluated in more than four studies; second trimester ß-core fragment (six studies), and second trimester ß-core
fragment with maternal age (five studies).
In direct test comparisons, for a 5% false positive rate (FPR), the diagnostic accuracy of the double marker second trimester ß-core
fragment and oestriol with maternal age test combination was significantly better (ratio of diagnostic odds ratio (RDOR): 2.2 (95%
confidence interval (CI) 1.1 to 4.5), P = 0.02) (summary sensitivity of 73% (CI 57 to 85) at a cut-point of 5% FPR) than that of
the single marker test strategy of second trimester ß-core fragment and maternal age (summary sensitivity of 56% (CI 45 to 66) at a
cut-point of 5% FPR), but was not significantly better (RDOR: 1.5 (0.8 to 2.8), P = 0.21) than that of the second trimester ß-core
fragment to oestriol ratio and maternal age test strategy (summary sensitivity of 71% (CI 51 to 86) at a cut-point of 5% FPR).
Authors’ conclusions
Tests involving second trimester ß-core fragment and oestriol with maternal age are significantly more sensitive than the single marker
second trimester ß-core fragment and maternal age, however, there were few studies. There is a paucity of evidence available to support
the use of urine testing for Down’s syndrome screening in clinical practice where alternatives are available.
P L A I N L A N G U A G E S U M M A R Y
Screening tests for Down’s syndrome in first 24 weeks of pregnancy
Background
Down’s syndrome (also known as Down’s or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental
health problems, and disabilities. However, there is wide variation in how Down’s affects people. Some individuals are severely affected
whilst others have mild problems and are able to lead relatively normal lives. There is no way of predicting how badly a baby might be
affected.
Expectant parents are given the choice to be tested for Down’s during pregnancy to assist them in making decisions. If a mother is
carrying a baby with Down’s, then there is the decision about whether to terminate or continue with the pregnancy. The information
offers parents the opportunity to plan for life with a Down’s child.
The most accurate tests for Down’s involve testing fluid from around the baby (amniocentesis) or tissue from the placenta (chorionic
villus sampling (CVS)) for the abnormal chromosomes associated with Down’s. Both these tests involve inserting needles through
the mother’s abdomen and are known to increase the risk of miscarriage. Thus, the tests are not suitable for offering to all pregnant
women. Rather, tests that measure markers in the mother’s blood, urine or on ultrasound scans of the baby are used for screening.
These screening tests are not perfect, they can miss cases of Down’s and also give a ‘high risk’ test results to a number of women whose
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babies are not affected by Down’s. Thus, pregnancies identified as ‘high risk’ using these screening tests require further testing using
amniocentesis or CVS to confirm a diagnosis of Down’s.
What we did
The aim of this review was to find out which of the urine screening tests done during the first 24 weeks of pregnancy are the most
accurate at predicting the risk of a pregnancy being affected by Down’s. We looked at seven different urine markers that can be used
alone, in ratios or in combination, taken before 24 weeks’ gestation, thus creating 24 screening tests for Down’s. We found 19 studies,
involving 18,013 pregnancies of which 527 had pregnancies affected by Down’s.
What we found
For the first 24 weeks of pregnancy, the evidence does not support the use of urine tests for Down’s syndrome screening. The amount
of evidence is limited. These tests are not offered in routine clinical practice.
Other important information to consider
The urine tests themselves have no adverse effects for the woman. However, some women who have a ‘high risk’ screening test result,
and are given amniocentesis or CVS have a risk of miscarrying a baby unaffected by Down’s. Parents will need to weigh up this risk
when deciding whether or not to have an amniocentesis or CVS following a ‘high risk’ screening test result.
B A C K G R O U N D
This is one of a series of reviews on antenatal screening for
Down’s syndrome following a generic protocol (Alldred 2010) -
see Published notes for more details.
Target condition being diagnosed
Down’s syndrome
Down’s syndrome affects approximately one in 800 live-born ba-
bies (Cuckle 1987a). It results from a person having three, rather
than two, copies of chromosome 21-or the specific area of chro-
mosome 21 implicated in causing Down’s syndrome, as a result of
trisomy or translocation. If not all cells are affected, the pattern is
described as ’mosaic’. Down’s syndrome can cause a wide range of
physical and mental problems. It is the commonest cause of men-
tal disability, and is also associated with a number of congenital
malformations, notably affecting the heart. There is also an in-
creased risk of cancers such as leukaemia, and numerous metabolic
problems including diabetes and thyroid disease. Some of these
problemsmay be life-threatening, or lead to considerable ill health,
while some individuals with Down’s syndrome have only mild
problems and can lead a relatively normal life.
There is no cure for Down’s syndrome, and antenatal diagnosis
allows for preparation for the birth and subsequent care of a baby
with Down’s syndrome, or for the offer of a termination of preg-
nancy. Having a baby with Down’s syndrome is likely to have a
significant impact on family and social life, relationships and par-
ents’ work. Special provisions may need to be made for education
and care of the child, as well as accommodating the possibility of
periods of hospitalisation.
Definitive invasive tests (amniocentesis and chorionic villus sam-
pling (CVS)) exist that allow the diagnosis of Down’s syndrome
before birth, but carry a risk of miscarriage. No test can predict
the severity of problems a person with Down’s syndrome will have.
Noninvasive screening tests based on biochemical analysis of ma-
ternal serum or urine, or fetal ultrasound measurements, allow
an estimate of the risk of a pregnancy being affected and provide
parents with information to enable them to make choices about
definitive testing. Such screening tests are used during the first and
second trimester of pregnancy.
Screening tests for Down’s syndrome
Initially, screening was determined solely by using maternal age to
classify a pregnancy as high or low risk for trisomy 21, as it was
known that older women had a higher chance of carrying a baby
with Down’s syndrome (Penrose 1933).
Further advances in screening were made in the early 1980s, when
Merkatz et al investigated the possibility that low maternal serum
alpha-fetoprotein (AFP), obtained frommaternal blood in the sec-
ond trimester of pregnancy could be associated with chromoso-
mal abnormalities in the fetus. Their retrospective case-control
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study showed a statistically significant relationship between fetal
trisomy, such as Down’s syndrome, and lowered maternal serum
AFP (Merkatz 1984). This was further explored by Cuckle et al in
a larger retrospective trial using data collected as part of a neural
tube defect (NTD) screening project (Cuckle 1984). This work
was followed by calculation of risk estimates using maternal serum
AFP values and maternal age, which ultimately led to the intro-
duction of the two screening parameters in combination (Alfirevic
2004).
In 1987, in a small case-control study of women carrying fe-
tuses with known chromosomal abnormalities, Bogart and col-
leagues investigated maternal serum levels of human chorionic go-
nadotrophin (hCG) as a possible screening tool for chromosomal
abnormalities in the second trimester (Bogart 1987). This fol-
lowed the observations that low hCG levels were associated with
miscarriages, which are commonly associated with fetal chromo-
somal abnormalities. They concluded that high hCG levels were
associated with Down’s syndrome and because hCG levels plateau
at 18 to 24 weeks, that this would be the most appropriate time
for screening. Later work suggested that the ß sub-unit of hCG
was a more effective marker than total hCG (Macri 1990; Macri
1993).
Second trimester unconjugated oestriol (uE3), produced by the
fetal adrenals and the placenta, was also evaluated as a potential
screening marker. In another retrospective case-control study, uE3
was shown to be lower in Down’s syndrome pregnancies compared
with unaffected pregnancies.Whenused in combinationwithAFP
andmaternal age, it appeared to identifymore pregnancies affected
by Down’s syndrome than AFP and age alone (Canick 1988).
Further work suggested that all three serum markers (AFP, hCG
and uE3) showed even higher detection rates when combined with
maternal age (Wald 1988a; Wald 1988b) and appeared to be a
cost-effective screening strategy (Wald 1992a).
Two other serum markers, produced by the placenta, have
been linked with Down’s syndrome, namely pregnancy-associ-
ated plasma protein A or PAPP-A, and Inhibin A. PAPP-A has
been shown to be reduced in the first trimester of Down’s syn-
drome pregnancies, with its most marked reduction in the early
first trimester (Bersinger 1995). Inhibin A is high in the second
trimester in pregnancies affected by Down’s syndrome (Cuckle
1995a; Wallace 1995). There are some issues concerning the bio-
logical stability and hence reliability of this marker, and the effect
this will have on individual risk.
In addition to serum and ultrasound markers for Down’s syn-
drome, work has been carried out looking at urinary markers.
These markers include invasive trophoblast antigen, ß-core frag-
ment, free ßhCG and total hCG (Cole 1999a). There is contro-
versy about their value (Wald 2003a).
Screening and parental choice
Antenatal screening is used for several reasons (Alfirevic 2004), but
the most important is to enable parental choice regarding preg-
nancymanagement and outcome. Before awoman and her partner
opt to have a screening test, they need to be fully informed about
the risks, benefits and possible consequences of such a test. This
includes the choices they may have to face should the result show
that the woman has a high risk of carrying a baby with Down’s
syndrome and the implications of both false positive and false neg-
ative screening tests. They need to be informed of the risk of a
miscarriage due to invasive diagnostic testing, and the possibility
that a miscarried fetus may be chromosomally normal. If, follow-
ing invasive diagnostic testing, the fetus is shown to have Down’s
syndrome, further decisions need to be made about continuation
or termination of the pregnancy, the possibility of adoption and
finally, preparation for parenthood. Equally, if a woman has a test
that shows she is at a low risk of carrying a fetus with Down’s
syndrome, it does not necessarily mean that the baby will be born
with a normal chromosomal make up. This possibility can only be
excluded by an invasive diagnostic test (Alfirevic 2003).The deci-
sions that may be faced by expectant parents inevitably engender
a high level of anxiety at all stages of the screening process, and the
outcomes of screening can be associated with considerable physi-
cal and psychological morbidity. No screening test can predict the
severity of problems a person with Down’s syndrome will have.
Index test(s)
This review examined urine screening tests used in the first and sec-
ond trimester of pregnancy (up to 24 weeks’ gestation) comprised
of the following individual markers; AFP; invasive trophoblast
antigen (ITA) (also knownas hyperglycosylated hCG); ß-core frag-
ment; free ßhCG; total hCG; uE3 (oestriol); gonadotropin pep-
tide; and various marker ratios. These markers can be used indi-
vidually, in combination with age, and can also be used in com-
bination with each other. The risks are calculated by comparing
a woman’s test result for each marker with values for an unaf-
fected population, and multiplying this with her age-related risk.
Where several markers are combined, risks are computed using
risk equations (often implemented in commercial software) that
take into account the correlational relationships between the dif-
ferentmarkers andmarker distributions in affected and unaffected
populations.
Alternative test(s)
Down’s syndrome can be detected during pregnancy with invasive
diagnostic tests such as amniocentesis or CVS, with or without
prior screening. These tests are considered to be reference tests
rather than index or screening tests. The ability to determine fetal
chromosomal make up (also known as a karyotype) from amniotic
fluid samples was demonstrated in 1966 by Steele and Breg (Steele
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1966), and the first antenatal diagnosis of Down’s syndrome was
made in 1968 (Vaklenti 1968). Amniocentesis is an invasive pro-
cedure that involves taking a small sample of the amniotic fluid
(liquor) surrounding the baby, using a needle which goes through
the abdominal wall into the uterus, and is usually performed after
15 weeks’ gestation. Chorionic villus sampling involves taking a
sample of the placental tissue using a needle which goes through
the abdominal wall and uterus or a cannula through the cervix.
It is usually performed between 10 and 13 weeks’ gestation. Am-
niocentesis and CVS are both methods of obtaining fetal chromo-
somematerial, which are then used to diagnose Down’s syndrome.
Both tests use ultrasound scans to guide placement of the needle.
Amniocentesis carries a risk of miscarriage in the order of 1%;
transabdominal CVSmay carry a similar risk (Alfirevic 2003). Re-
cent developments in the use of cell-free fetal DNA detection in
maternal serum are paving the way for noninvasive diagnosis of
Down’s syndrome and other trisomies, however these tests were
not used as reference standards in any of the studies examined.
Many different screening tests are available and offered to preg-
nant women, and these tests are the subject of additional Cochrane
reviews published (Alldred 2012) or currently in preparation, and
other published reviews. Tests being assessed in other Cochrane
reviews include first trimester serum tests; second trimester serum
tests; first trimester ultrasound markers; tests that combine serum
and ultrasound markers; and tests that combine markers from the
first trimester with markers from the second trimester. Second
trimester ultrasound markers have been assessed in a previous sys-
tematic review (Smith-Bindman 2001).
Rationale
This is one of a suite of Cochrane reviews, the aim of which is to
identify all screening tests for Down’s syndrome used in clinical
practice, or evaluated in the research setting, in order to try to iden-
tify the most accurate test(s) available, and to provide clinicians,
policy-makers and women with robust and balanced evidence on
which to base decisions about interpreting test results and imple-
menting screening policies to triage the use of invasive diagnostic
testing. The full set of reviews is described in the generic protocol
(Alldred 2010).
The topic has been split into several different reviews to allow for
greater ease of reading and greater accessibility of data, and also to
allow the reader to focus on separate groups of tests, for example,
first trimester serum tests alone, first trimester ultrasound alone,
first trimester serumandultrasound, second trimester serumalone,
first and second trimester serum, combinations of serum and ul-
trasound markers and urine markers alone. An overview review
will compare the best tests, focusing on commonly used strategies
from each of these groups to give comparative results between the
best tests in the different categories. This review is written with
a global perspective in mind, rather than to conform with any
specific local or national policy, as not all tests will be available in
all areas where screening for Down’s syndrome is carried out.
A systematic review of second trimester ultrasound markers in
the detection of Down’s syndrome fetuses was published in 2001
that concluded that nuchal fold thickening may be useful in de-
tecting Down’s syndrome, but that it was not sensitive enough
to use as a screening test. The review concluded that the other
second trimester ultrasound markers did not usefully distinguish
between Down’s syndrome and pregnancies without Down’s syn-
drome (Smith-Bindman 2001). There has yet to be a systematic
review and meta-analysis of the observed data on serum, urine
and first trimester ultrasound markers, in order to draw rigorous
and robust conclusions about the diagnostic accuracy of available
Down’s syndrome screening tests.
O B J E C T I V E S
The aim of this review was to estimate and compare the accu-
racy of first and second trimester urine markers for the detection
of Down’s syndrome in the antenatal period, both as individual
markers and as combinations of markers. Accuracy is described
by the proportion of fetuses with Down’s syndrome detected by
screening before birth (sensitivity or detection rate), and the pro-
portion of women with a low risk (normal) screening test result
who subsequently had a baby unaffected by Down’s syndrome
(specificity). We grouped our analyses to focus on investigating
the value of adding increasing numbers of markers (comparing
single, dual, triple and quadruple tests).
Investigation of sources of heterogeneity
We planned to investigate whether a uniform screening test is suit-
able for all women, or whether different screening methods are
more applicable to different groups, defined by advanced mater-
nal age, ethnic groups and aspects of the pregnancy and medical
history such as multiple pregnancy, diabetes and family history
of Down’s syndrome. We also considered whether there existed
evidence of overestimation of test accuracy in studies evaluating
risk equations in the derivation sample rather than in a separate
validation sample.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included studies in which all women from a given popula-
tion had one or more index test(s) compared to a reference stan-
dard. Both consecutive series and diagnostic case-control study
designs were included. Randomised trials where individuals were
randomised to different screening strategies and all verified using
a reference standard were also eligible for inclusion. Studies in
which test strategies were compared head-to-head, either in the
same women, or between randomised groups were identified for
inclusion in separate comparisons of test strategies. Studies were
excluded if they included less than five Down’s syndrome cases, or
more than 20% of participants were not followed up.
Participants
Pregnant women at less than 24 weeks’ gestation confirmed by
ultrasound, who had not undergone previous testing for Down’s
syndrome in their pregnancy were eligible. Studies were included
if the pregnant women were unselected, or if they represented
groups with increased risk of Down’s syndrome, or difficulty with
conventional screening tests including maternal age greater than
35 years old, multiple pregnancy, diabetes mellitus and family
history of Down’s syndrome.
Index tests
The following index tests were examined; AFP; ITA; ß-core frag-
ment; free ßhCG; total hCG; oestriol (also termed as uE3); go-
nadotropin peptide and variousmarker ratios and combinations of
these markers combined with maternal age. Combinations with-
out maternal age were not included in the test comparisons (Table
1; Table 2), however, information on such test combinations is
provided.
We looked at comparisons of tests in isolation and in various
combinations. These included single (one marker), double (two
markers), triple (three markers), test strategies, all maternal age-
adjusted.
Where tests were used in comparison, we looked at the perfor-
mance of test comparisons according to predicted probabilities
computed using risk equations and dichotomised into high risk
and low risk.
Target conditions
Down’s syndrome in the fetus due to trisomy, translocation or
mosaicism.
Reference standards
Weconsidered several reference standards, involving chromosomal
verification and postnatal macroscopic inspection.
Amniocentesis and CVS are invasive chromosomal verification
tests undertaken during pregnancy. They are highly accurate, but
the process carries a 1% miscarriage rate, and therefore they are
only used in pregnancies considered to be at high risk of Down’s
syndrome, or on the mother’s request. All other types of testing
(postnatal examination, postnatal karyotyping, birth registers and
Down’s syndrome registers) are based on information available at
the end of pregnancy. The greatest concern is not their accuracy,
but the loss of the pregnancy to miscarriage between the urine test
and the reference standard. Miscarriage with cytogenetic testing
of the fetus is included in the reference standard where available.
We anticipated that older studies, and studies undertaken in older
women were more likely to have used invasive chromosomal ver-
ification tests in all women.
Studies undertaken in younger women and more recent studies
were likely to use differential verification as they often only used
prenatal karyotypic testing on fetuses considered screen positive/
high risk according to the screening test; the reference standard for
most unaffected infants being observing a phenotypically normal
baby. Although the accuracy of this combined reference standard
is considered high, it is methodologically a weaker approach as
pregnancies that miscarry between the index test and birth are
likely to be lost from the analysis, and miscarriage is more likely
to occur in Down’s than normal pregnancies. We investigated the
impact of the likely missing false negative results in sensitivity
analyses.
Search methods for identification of studies
Electronic searches
We applied a sensitive search strategy to search the following
databases. We used one broad generic search strategy to identify
studies for all reviews in this series.
Databases searched included;
• MEDLINE via OVID (1980 to 25 August 2011)
• EMBASE via Dialog Datastar (1980 to 25 August 2011)
• BIOSIS via EDINA (1985 to 25 August 2011)
• CINAHL via OVID (1982 to 25 August 2011)
• The Database of Abstracts of Reviews of Effectiveness (The
Cochrane Library 2011, Issue 7)
• MEDION (25 August 2011)
• The Database of Systematic Reviews and Meta-Analyses in
Laboratory Medicine (www.ifcc.org/) (25 August 2011)
• The National Research Register (archived 2007)
• Health Services Research Projects in Progress database (
HSRPROJ) (25 August 2011)
The search strategy combined three sets of search terms (see
Appendix 1). The first set was made up of named tests, general
terms used for screening/diagnostic tests and statistical terms.Note
that the statistical terms were used to increase sensitivity and were
not used as a methodological filter to increase specificity. The sec-
ond set was made up of terms that encompass Down syndrome
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and the third set made up of terms to limit the testing to pregnant
women. All termswithin each set were combinedwith the Boolean
operator OR and then the three sets were combined using AND.
The terms used were a combination of subject headings and free
text terms. The search strategy was adapted to suit each database
searched.
We attempted to identify cumulative papers that reported data
from the same data set, and we contacted authors to obtain clari-
fication of the overlap between data presented in these papers, in
order to prevent data from the same women being analysed more
than once.
Searching other resources
In addition, we examined references cited in studies identified as
being potentially relevant, and those cited by previous reviews.
We contacted authors of studies where further information was
required. We did not apply a diagnostic test filter, and we did not
apply language restrictions to the search.
We carried out forward citation searching of relevant items, us-
ing the search strategy in ISI citation indices, Google scholar and
Pubmed ‘related articles’.
Data collection and analysis
Selection of studies
Two review authors screened the titles and abstracts (where avail-
able) of all studies identified by the search strategy. We obtained
full-text versions of studies identified as being potentially relevant
and two review authors independently assessed these for inclusion,
using a study eligibility screening pro forma according to the pre-
specified inclusion criteria. Any disagreement between the two re-
view authors was settled by consensus, or where necessary, by a
third party.
Data extraction and management
We developed a data extraction form and piloted the form using
a subset of 20 identified studies (from all identified studies in
this suite of reviews). Two review authors independently extracted
data, andwhere disagreement or uncertainty existed, a third review
author validated the information extracted.
Data on each marker were extracted as binary test positive/test
negative results for Down’s and non-Down’s pregnancies, with a
high risk-result, as definedby each individual study, being regarded
as test positive (suggestive or diagnostic of Down’s syndrome),
and a low-risk result being regarded as test negative (suggestive
of absence of Down’s syndrome). Where results were reported at
several thresholds, we extracted data at each threshold.
We noted those in special groups that posed either increased risk of
Down’s syndrome or difficulty with conventional screening tests,
including maternal age greater than 35 years old, multiple preg-
nancy, diabetes mellitus and family history of Down’s syndrome.
Assessment of methodological quality
Weused amodified version of theQUADAS tool (Whiting 2003),
a quality assessment tool for use in systematic reviews of diagnostic
accuracy studies, to assess the methodological quality of included
studies. We anticipated that a key methodological issue would be
the potential for bias arising from the differential use of invasive
testing and follow-up for the reference standard according to in-
dex test results, bias arising due to higher loss to miscarriage in
false negatives than true negatives. We chose to code this issue
as originating from differential verification in the QUADAS tool:
we are aware that it could also be coded under delay in obtaining
the reference standard, and reporting of withdrawals. We omit-
ted the QUADAS item assessing quality according to length of
time between index and reference tests, as Down’s syndrome is
either present or absent rather than a condition that evolves and
resolves, and disregarding the differential reference standard issue
thus any length of delay is acceptable. Two review authors assessed
each included study separately. Any disagreement between the two
authors was settled by consensus, or where necessary, by a third
party. Each item in the QUADAS tool was marked as ‘yes’, ‘no’ or
‘unclear’, and scores were summarised graphically. We did not use
a summary quality score.
QUADAS criteria included the following 10 questions.
1. Was the spectrum of women representative of the women
who will receive the test in practice? (Criteria met if the sample
was selected from a wide range of childbearing ages, or selected
from a specified ‘high-risk’ group such as over 35s, family history
of Down’s syndrome, multiple pregnancy or diabetes mellitus,
provided all affected and unaffected fetuses included that could
be tested at the time point when the screening test would be
applied; criteria not met if the sample taken from a select or
unrepresentative group of women (i.e. private practice), was an
atypical screening population or recruited at a later time point
when selection could be affected by selective fetal loss).
2. Is the reference standard likely to correctly classify the target
condition? (Amniocentesis, CVS, postnatal karyotyping,
miscarriage with cytogenetic testing of the fetus, a phenotypically
normal baby or birth registers are all regarded as meeting this
criteria).
3. Did the whole sample or a random selection of the sample
receive verification using a reference standard of diagnosis?
4. Did women receive the same reference standard regardless
of the index test result?
5. Was the reference standard independent of the index test
result (i.e. the index test did not form part of the reference
standard)?
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6. Were the index test results interpreted without knowledge
of the results of the reference standard?
7. Were the reference standard results interpreted without
knowledge of the results of the index test?
8. Were the same clinical data (i.e. maternal age and weight,
ethnic origin, gestational age) available when test results were
interpreted as would be available when the test is used in practice?
9. Were uninterpretable/intermediate test results reported?
10. Were withdrawals from the study explained?
Statistical analysis and data synthesis
We initially examined each test or test strategy at each of the com-
mon risk thresholds used to define test positivity by plotting esti-
mates of sensitivity and specificity from each study on forest plots
and in receiver operating characteristic (ROC) space. Test strate-
gies were selected for further investigation if they were evaluated
in four or more studies or, if there were three or fewer studies,
but the individual study results indicated performance likely to be
superior to a sensitivity of 70% and specificity of 90%.
Estimation of average sensitivity and specificity
The analysis for each test strategy was undertaken first restricting
to studies that reported a common threshold to estimate average
sensitivity and specificity for each test at each threshold. Although
data on all thresholds were extracted, we present only key common
thresholds close to risks of 1:384, 1:250 and the 5% false positive
rate (FPR), unless other thresholdsweremore commonly reported.
Where combinations of tests were used in a risk score, we extracted
the result for the test combination using the risk score and not the
individual components that made up the test.
We undertook meta-analyses using hierarchical summary ROC
(HSROC)models, which included estimationof random effects in
accuracy and threshold parameters when there were four or more
studies. Otherwise, average sensitivity and specificity values were
computed by using univariate random-effects logistic regression
models to average logit sensitivity and logit specificity separately
because of insufficient number of studies to reliably estimate all
the parameters in the HSROC model. It is common in this field
for studies to report sensitivity for a fixed specificity (usually a
5% FPR). This removes the requirement to account for the cor-
relation between sensitivity and specificity across studies by using
a bivariate meta-analytical method since all specificities are the
same value. Thus, at a fixed specificity value, logit sensitivities were
pooled using a univariate random-effects model. This model was
further simplified to a fixed-effect model when there were only
two or three studies and heterogeneity was not observed on the
SROC plot. All analyses were undertaken using the NLMIXED
procedure in SAS (version 9.2; SAS Institute, Cary, NC) and the
xtmelogit command in Stata version 11.2 (Stata-Corp, College
Station, TX, USA).
Comparisons between tests
We made comparisons between tests, first by utilising all avail-
able studies, selecting one threshold from each study to estimate
a SROC curve without restricting to a common threshold. The
threshold was chosen for each study according to the following
order of preference: a) the risk threshold closest to one in 250; b)
a multiples of the median (MoM) or presence/absence threshold;
c) the performance closest to a 5% FPR or 95th percentile. The
5% FPR was chosen as a cut-off point as this is the cut-off most
commonly reported in the literature. The analysis that used all
available studies was performed by including the most evaluated
or best performing test strategies in a single HSROC model. The
model included two indicator terms for each test to allow for dif-
ferences in accuracy and threshold. As there were very few studies
for each test, a symmetric summary ROC curve was assumed. In
addition, because the model failed to converge, we assumed fixed-
effect for the threshold and accuracy parameters. An estimate of
the sensitivity of each test for a 5% FPR was derived from the
SROC curve, and we obtained associated confidence intervals us-
ing the delta method.
Direct comparisons between tests were based on results of very few
studies, and were analysed using a simplified HSROCmodel with
fixed-effect and symmetrical underlying SROC curves because the
number of studies was insufficient to estimate between study het-
erogeneity in accuracy and threshold or asymmetry in the shape
of the SROC curves. We used a separate model to make each pair-
wise comparison. We assessed comparisons between tests by using
likelihood ratio tests to test if the differences in accuracy were sta-
tistically significant or not. We expressed the differences as ratios
of diagnostic odds ratios and reported with 95% confidence inter-
vals. As studies rarely report data cross-classified by both tests for
Down’s and normal pregnancies, the analytical method did not
take full account of the pairing of test results, but the restriction
to direct head-to-head comparisons should have removed the po-
tential confounding of test comparisons with other features of the
studies. The strength of evidence for differences in performance of
test strategies relied on evidence from both the direct and indirect
comparisons.
Investigations of heterogeneity
Had there been 10 or more studies available for a test, we planned
to investigate heterogeneity by adding covariate terms to the
HSROC model to assess the effect of a covariate on accuracy and
threshold.
Sensitivity analyses
In many of the included studies, mothers with pregnancies iden-
tified as high risk for Down’s syndrome by the urine testing were
offered immediate definitive testing by amniocentesis, whereas the
remainder were assessed for Down’s syndrome by inspection at
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birth. Such delayed and differential verification will introduce bias
most likely through there being greater loss to miscarriage in the
Down’s syndrome pregnancies that were not detected by the urine
testing (the false negative diagnoses). Testing and detection of mis-
carriages is impractical in many situations, and no clear data are
available on the magnitude of these miscarriage rates.
To account for the possible bias introduced by such a mechanism,
we planned to perform sensitivity analyses by increasing the per-
centage of false negatives in studies where delayed verification in
test negatives occurred (Mol 1999). We planned to incrementally
increase the percentage from 10% to 50%, the final value repre-
senting a scenario where a third of more Down’s pregnancies than
normal pregnancies were likely to miscarry, thought to be higher
than the likely value. We intended to conduct the sensitivity anal-
yses on the analysis investigating the effect of maternal age on test
sensitivity.
R E S U L T S
Results of the search
The search for the whole suite of reviews identified a total of
15,394 papers, once the results from each bibliographic database
were combined and duplicates were removed. After screening out
obviously inappropriate papers based on their title and abstract,
1145 papers remained and we obtained full-text copies for formal
assessment of eligibility. From these, a total of 269 papers were
deemed eligible and were included in the suite of reviews. We
included a total of 19 studies (reported in 29 publications) in this
review of urine tests, involving 18,013 pregnancies, of which 527
were Down’s syndrome pregnancies.
A total of 24 different test strategies or combinations, at one or
more thresholds, were evaluated in the 19 studies. These tests were
produced from combinations of seven different urine tests (and
their ratios) with andwithoutmaternal age: AFP; ITA; ß-core frag-
ment; free ßhCG; total hCG; oestriol; gonadotropin peptide and
various marker ratios. Strategies evaluated included three double
tests and seven single tests in combination with maternal age, and
one triple test, two double tests and 11 single tests without mater-
nal age. Twelve of the 19 studies only evaluated the performance
of a single test strategy while the remaining seven evaluated at least
two test strategies.
The following combinations evaluated included four ormore stud-
ies.
1. Second trimester ß-core fragment (six studies; 9615 women
with 193 affected Down’s pregnancies)
2. Second trimester ß-core fragment and maternal age (five
studies; 3419 women with 155 Down’s pregnancies)
Methodological quality of included studies
We judged the studies to be of highmethodological quality inmost
categories (Figure 1). Due to the nature of testing for Down’s syn-
drome screening and the potential side effects of invasive testing,
differential verification is almost universal in the general screening
population, as most women whose screening test result is defined
as low risk will have their screening test verified at birth, rather
than by invasive diagnosis in the antenatal period. Additionally,
it was not always possible to ascertain from the included studies
whether or not the results of index tests and reference standards
were blinded. It would be difficult to blind clinicians performing
invasive diagnostic tests (reference standards) to the index test re-
sult, unless all women received the same reference standard, which
would not be appropriate in most scenarios. Any biases secondary
to a lack of clinician blinding are likely to be minimal.
9Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Most studies seemed to indicate 100% follow-up, however there
will inevitably be losses to follow-up due to women moving out
of area, for example. Studies sometimes accounted for these and
it is unlikely that there were enough losses to follow-up to have
introduced significant bias. There was likely under-ascertainment
of miscarriage, and very few papers accounted for miscarriage, or
performed tissue karyotyping in pregnancies resulting in miscar-
riage. Some studies attempted to adjust for predicted miscarriage
rate and the incidence of Down’s syndrome in this specific pop-
ulation, but most did not. We have not attempted to adjust for
expected miscarriage rate in this review. There is a higher natural
miscarriage rate in the first trimester, however this will be uniform
across studies and therefore unlikely to introduce significant bias.
Some studies that provided estimates of risk using multivariable
equations used the same data set to evaluate performance of the
risk equation as was used to derive the equation. This is often
thought to lead to over-estimation of test performance.
Findings
1) Second trimester ß-core fragment
Results for this single test were derived from six studies (Cole
1999b; Cuckle 1995b; Cuckle 1999a; Isozaki 1997; Spencer 1996;
Wald 2003), and included 9615 women in whom 193 pregnancies
were known to be affected by Down’s syndrome. Two studies (
Cole 1999b; Cuckle 1999a) contributed over 7000 pregnancies to
the data. Six studies (Cole 1999b; Cuckle 1995b; Cuckle 1999a;
Isozaki 1997; Spencer 1996; Wald 2003) presented data for a cut-
point of 5% FPR and the estimated sensitivity was 41% (95%
confidence interval (CI) 20 to 66).
2) Second trimester ß-core fragment and maternal
age
Results for this single test were derived from five studies (
Bahado-Singh 1999; Bahado-Singh 1999a; Cole 1999b; Hsu
1999; Spencer 1996), and included 3419 women in whom 155
pregnancies were known to be affected by Down’s syndrome. Cole
1999b contributed over 1000 pregnancies to the data. The studies
presented data at a cut-point of 5% FPR and the summary sensi-
tivity was 56% (95% CI 45 to 66).
3) Other test combinations
Of the 22 test combinations evaluated in three or fewer stud-
ies, nine test combinations demonstrated estimated sensitivities of
more than 70% and estimated specificities of more than 90%. Six
of these were evaluated in single studies (see Summary of findings),
and the following three test combinations were evaluated in two
or more studies.
1. Second trimester ß-core fragment to oestriol ratio
evaluated in two studies (Cole 1997b; Cole 1999b), with a
summary sensitivity of 74% (95% CI 58 to 86) at a cut-point of
5% FPR.
2. Second trimester ß-core fragment to oestriol ratio and
maternal age evaluated in three studies (Bahado-Singh 1999;
Cole 1999b; Hsu 1999), with a summary sensitivity of 71%
(95% CI 51 to 86) at a cut-point of 5% FPR.
3. Second trimester ß-core fragment, oestriol and maternal
age evaluated in two studies (Cole 1999b; Hsu 1999), with a
summary sensitivity of 73% (95% CI 57 to 85) at a cut-point of
5% FPR.
Comparative analyses of the five selected test
strategies
For each test we obtained the detection rate (sensitivity) for a fixed
FPR (1-specificity), a metric which is commonly used in Down’s
syndrome screening to describe test performance. We chose to
estimate detection rates at a 5% FPR in common with much of
the literature. Figure 2 shows point estimates of the detection rate
(and their 95% CIs) at a 5% FPR based on all available data for
the five test strategies; the test strategies are ordered according to
decreasingdetection rates. The plot shows that all five test strategies
have detection rates between 56% and 90%. The combination of
second trimester AFP and ß-core fragment to oestriol ratio with
maternal age showed the highest detection rate with an estimated
detection rate of 90% (CI 55 to 100), based on data from one
study with 10 affected cases out of a total of 356 pregnancies. The
worst performing strategywas the combination of ß-core fragment
to oestriol ratio and maternal age, with an estimated detection rate
of 56% (CI 45 to 66), based on data from five studies with 155
affected cases out of a total of 3419 pregnancies.
11Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Detection rates (% sensitivity) at a 5% false positive rate for the five most evaluated or best
performing test strategies. The estimates are shown with 95% confidence intervals. The test strategies are
ordered on the plot according to decreasing detection rate. The number of studies, cases and women included
for each test strategy are shown on the horizontal axis.
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Table 1 shows pair-wise direct comparisons (head-to-head) where
studies were available. Such comparisons are regarded as providing
the strongest evidence as they are unconfounded. The table shows
the ratio of diagnostic odds ratio (RDOR) with 95% CI and P
values for each test combination, the number of studies (K) for
which data were available. The table shows that the diagnostic
accuracy of the double marker combination of second trimester
ß-core fragment and oestriol with maternal age was significantly
better (RDOR 2.2 (95% CI 1.1 to 4.5); P = 0.02) than the single
marker second trimester ß-core fragment and maternal age test
strategy but was not significantly better (RDOR 1.5 (95% CI
0.8 to 2.8); P = 0.21) than that of the second trimester ß-core
fragment to oestriol ratio and maternal age test strategy. However,
the comparisons in this table were based on two or three studies
and are unlikely to be powered to detect differences in detection
rates.
Table 2 shows the same comparisons made using all available data
(as used to create Figure 2). Results are in agreementwith the direct
comparisons, and in addition, showed no significant differences
between any of the other pair of tests for which direct comparisons
were not available. However, these comparisons are potentially
confounded by differences between the studies, and the evidence
is limited.
Investigation of heterogeneity and sensitivity analyses
None of the tests was evaluated by 10 or more studies and so we
were unable to investigate the effect of maternal age or any other
potential source of heterogeneity. The planned sensitivity analyses,
looking at differential verification and any resultant bias, were also
not possible.
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Summary of findings
Review Question What is the accuracy of urine based markers for screening for Down’s syndrome?
Population Pregnant women at less than 24 weeks’ gestation confirmed by ultrasound, who had not undergone previous testing for Down’s syndrome. Most studies were
undertaken in women identified to be high risk based on maternal age
Settings All settings
Numbers of studies, preg-
nancies and Down’s syn-
drome cases
19 studies (reported in 29 publications) involving 18,013 pregnancies of which 527 were Down’s syndrome pregnancies
Index tests Risk scores computed using maternal age and first and second trimester urine markers for AFP; ITA; ß -core fragment; free ßhCG; total hCG; oestriol (also
termed as uE3); gonadotropin peptide
Reference standards Chromosomal verification (amniocentesis and CVS undertaken during pregnancy, and postnatal karyotyping) and postnatal macroscopic inspection
Study limitations Seven studies only used selective chromosomal verification during pregnancy, and were at risk of under-ascertainment of Down’s syndrome cases due loss
of the pregnancy to miscarriage between the serum test and the reference standard
Test Studies Women (Cases) Sensitivity* (95% CI) Specificity* (95% CI) Threshold
Test without maternal age
Single tests
First trimester free ßhCG 1 516 (86) 5 (1 to 11) 95 (92 to 97) 5% FPR
First trimester ß -core frag-
ment
1 516 (86) 10 (5 to 19) 95 (92 to 97) 5% FPR
First trimester ITA 2 579 (94) 15 (2 to 62) 95 5% FPR
First trimester total hCG 1 516 (86) 17 (10 to 27) 95 (92 to 97) 5% FPR1
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Second trimester oestriol 2 1472 (47) 23 (8 to 49) 95 5% FPR
Second trimester total hCG 1 390 (65) 31 (20 to 43) 95 (92 to 97) 5% FPR
Second trimester free ßhCG 3 1517 (107) 32 (12 to 63) 95 5% FPR
Second trimester ß -core frag-
ment
6 9613 (193) 41 (20 to 66) 95 5% FPR
Second trimester ITA 3 2748 (131) 43 (35 to 51) 95 5% FPR
Second trimester ß -core frag-
ment to oestriol ratio
2 1649 (35) 74 (58 to 86) 95 5% FPR
Second trimester
gonadotropin test
1 105 (14) 93 (66 to 100) 95 (88 to 98) 1:384 risk
Double tests
Second trimester AFP and ITA 1 524 (24) 79 (58 to 93) 95 (93 to 97) 5% FPR
Second trimester ß -core frag-
ment and oestriol
1 315 (24) 83 (63 to 95) 95 (92 to 97) 5% FPR
Triple tests
Second trimester AFP, uE3
and ITA
1 524 (24) 79 (58 to 93) 95 (93 to 97) 5% FPR
Test with maternal age
Single tests
Second trimester oestriol 1 474 (69) 49 (37 to 62) 95 (92 to 97) 5% FPR
Second trimester ß -core frag-
ment
5 3419 (155) 56 (45 to 66) 95 5% FPR
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Second trimester free ßhCG 2 879 (98) 57 (47 to 67) 95 5% FPR
Second trimester free ßhCG to
oestriol ratio
1 474 (69) 64 (51 to 75) 95 (92 to 97) 5% FPR
Second trimester ß -core frag-
ment to free ßhCG
1 474 (69) 67 (54 to 78) 95 (92 to 97) 5% FPR
Second trimester ITA 1 1016 (23) 70 (47 to 87) 95 (93 to 96) 5% FPR
Second trimester ß -core frag-
ment to oestriol ratio
3 2088 (105) 71 (51 to 86) 95 5% FPR
Double tests
Second trimester oestriol and
free ßhCG
1 474 (69) 68 (56 to 79) 95 (92 to 97) 5% FPR
Second trimester ß -core frag-
ment and oestriol
2 1631 (92) 73 (57 to 85) 95 5% FPR
Second trimester AFP and ß-
core fragment to oestriol ratio
1 356 (10) 90 (55 to 100) 95 (93 to 97) 1:58 risk
*Tests evaluated by at least one study are presented in the table. Where two studies reported the same threshold, estimates of summary
sensitivity and summary specificity were obtained by using univariate fixed effects logistic regression models to pool sensitivities and
specificities separately. if the threshold used was a 5% FPR, then only the sensitivities were pooled.
AFP: alpha-fetoprotein; ßhCG: beta human chorionic gonadotrophin;CI: confidence interval; CVS: chorionic villus sampling; FPR: false
positive rate; hCG: beta human chorionic gonadotrophin;ITA: invasive trophoblast antigen; uE3: unconjugated oestriol
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D I S C U S S I O N
Summary of main results
The systematic review found 19 studies evaluating urinary mark-
ers for Down’s syndrome screening. Very few studies provided un-
confounded comparisons of test strategies by applying and com-
paring several strategies using the same urine sample; the majority
of studies only evaluating a single test combination. A summary
of results for the 24 strategies is given in Summary of findings.
The following key findings were noted.
1. There is evidence from direct comparison to support the
use of multiple marker urine tests in combination with age for
screening - the double marker combination of second trimester
ß-core fragment and oestriol with maternal age test strategy was
significantly better (ratio of diagnostic odds ratio (RDOR) 2.2
(95% CI 1.1 to 4.5); P = 0.02) than the single marker second
trimester ß-core fragment and maternal age. This is reflected in
the indirect comparison of the two tests.
2. There was little evidence that urine markers are of value in
screening for Down’s syndrome. Marker combinations evaluated
by more than three studies showed low detection rates for a 5%
false positive rate (FPR). More promising markers were
investigated in fewer than three studies.
3. In indirect comparisons, with the exception of the
difference in accuracy between the single marker second
trimester ß-core fragment and maternal age test and the double
marker combination of second trimester ß-core fragment and
oestriol with maternal age, there was no significant difference in
the detection rates between tests, however, the number of
included studies was small.
Strengths and weaknesses of the review
This is the first comprehensive systematic review of urine tests for
Down’s syndrome screening. We examined papers from around
the world, covering a wide cross-section of women in varying
populations. We contacted authors to verify data where necessary
to give as complete a picture as possible while trying to avoid
replication of data.
There were a number of factors that have made meta-analysis of
the data difficult, which we have tried to adapt for in order to
allow for comparability of data presented in different studies.
1. There were many different cut-points used to define
pregnancies as high or low risk for Down’s syndrome. This
means that direct comparison is more difficult than if all studies
used the same cut-point to dichotomise their populations.
2. There were many different risk equations and software
applications in use for combination of multiple markers, which
were often not described in the papers. This means that risks
may be calculated by different formulae, and they may not be
directly comparable for this reason.
3. Different laboratories and clinics run different assays and
use different machines and methods. This may influence raw
results and subsequent risk calculations. Many laboratories have
a quality assessment/audit trail, however, this may not necessarily
be standard across the board, for example, how many assays are
run, how often medians are calculated and adjusted for a given
population and how quickly samples are tested from initially
being taken.
4. Very few studies make direct comparisons between tests,
making it difficult to detect if there is a real difference between
tests (i.e. how different tests perform in the same population).
There are differences in populations, with assay medians being
affected, for example, by race. It is not certain whether it is
appropriate to make comparisons between populations which are
inherently different.
5. We were unable to perform any of the subgroup analyses
that we had originally intended to, as the data simply were not
available. The vast majority of papers looking at pregnancies
conceived by in vitro fertilisation (IVF), affected by diabetes,
multiple gestation or a family history of Down’s syndrome
involved unaffected pregnancies only.
Applicability of findings to the review question
When planning a screening policy or a clinical screening pro-
gramme, clinicians and policy makers need to make decisions
about a finite number of tests or type of tests that can be offered.
These policies are often driven by both the needs of a specific pop-
ulation and by financial resources. Economic analysis was con-
sidered to be outside the scope of this review. Many of the tests
examined as part of this review are already commercially available
and in use in the clinical setting. The studies were carried out on
populations of typical pregnant women and therefore, the results
should be considered comparable with most pregnant populations
encountered in every day clinical practice.
We were unable to extract information about the harms of testing,
information about miscarriage rates and uptake of definitive test-
ing as the data were not often available. While it is unlikely that
major differences between the tests evaluated here exist in terms
of direct harms of testing, as they are all based on a single urine
sample, differences in accuracy may lead to differences in the use
of definitive testing and its consequent adverse outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Urine testing for Down’s syndrome is not commonly used, with
serum and ultrasound testing being widely clinically available.
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We would not recommend the introduction of urine testing for
Down’s syndrome screening on the basis of the review findings,
or that urine testing should replace serum or ultrasound testing
where it is available. There is a paucity of evidence available to
support the use of urine testing in clinical practice where alterna-
tives are available.
Implications for research
Further evaluation of urine tests is required before definitive rec-
ommendations canbemade about their use in clinical practice. Fu-
ture studies should ensure that adequate sample sizes are recruited,
and make comparisons of several alternative test combinations on
the same urine samples. Such direct comparisons minimise con-
founding and allow a clear focus on testing the incremental ben-
efit of increasingly complex and expensive testing strategies. The
reporting of test accuracy studies can be improved by adhering to
the STARD reporting guideline Bossuyt 2003. Three key aspects
are: 1) formally testing the statistical significance of differences in
test performance in direct comparisons and estimating incremen-
tal changes in detection rates (together with confidence intervals),
2) clearly reporting the number of mothers studied and their re-
sults, and 3) reporting the numbers of women who are lost to
follow-up.
For the purposes of meta-analysis and to allow for comparisons
to be made between different tests and combinations, we recom-
mend the publication of consensus standard algorithms for esti-
mating risk, and reporting of test performance at a standard set of
thresholds. This would be difficult to achieve and implement, but
an attempt at consensus should be made.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bahado-Singh 1998
Clinical features and settings High-risk referral for invasive testing.
Participants 511 participants.
USA.
August 1996 to January 1997.
Singleton pregnancies.
Pregnant women.
Mean age 37.1 years (SD 2.8 years).
15-24 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 18 cases.
Reference standard: amniocentesis.
Index and comparator tests Mid-trimester urine ß-core fragment testing (monoclonal antibody B210 assay, 2-step
sandwich method, standardised for creatinine)
Follow-up 100% karyotyping.
Aim of study To ascertain the screening efficiency of a new mid-trimester Down’s syndrome detection
protocol that combines maternal urine testing and ultrasonographic examination
Notes Amniocentesis was being conducted on the basis of maternal age. Women who have
amniocentesis just due to abnormal screening results were excluded from the study
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women underwent the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
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Bahado-Singh 1998 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results.
Index test results blinded?
All tests
Yes Urine testing was conducted blind from the re-
sults of amniocentesis.
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Bahado-Singh 1998b
Clinical features and settings High-risk referral for invasive testing.
Participants 356 participants: 10 cases and 346 controls.
USA.
Dates not reported.
Singleton pregnancies.
Pregnant women.
14-24 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 10 cases.
Reference standard: amniocentesis.
Index and comparator tests Seond trimester urine ß-core fragment testing (monoclonal antibody B210 assay, 2-step
sandwich method, standardised for creatinine)
Second trimester serum AFP.
Risk cut points of 1/10, 1/20, 1/30, 1/58, 1/270, 1/526.
Follow-up 100% karyotyping.
Aim of study To determine Down’s syndrome screening efficiency of a new protocol that combines
maternal serum AFP and beta core fragment/total oestriol ratio
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Bahado-Singh 1998b (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women underwent a reference standard.
Differential verification avoided?
All tests
Yes All women underwent the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Bahado-Singh 1999
Clinical features and settings High-risk referral for invasive testing.
Participants 457 participants.
USA.
August 1996 - June 1997.
Pregnant women.
Mean age 37.1 years.
Singleton pregnancies.
15-24 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 13 cases.
Reference standard: amniocentesis.
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Bahado-Singh 1999 (Continued)
Index and comparator tests Maternal age.
Urinary ß core fragment (monoclonal antibody B210 assay, 2-step sandwich method,
standardised for creatinine)
Urinary beta core fragment/total urinary oestriol ratio.
Follow-up 100% karyotyping.
Aim of study To evaluate Down’s syndrome screening efficiency of a new algorithm of multiple urinary
biochemical and ultrasound markers
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women received the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results.
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results.
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
47Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bahado-Singh 1999a
Clinical features and settings High-risk referral for invasive testing.
Participants 926 participants.
USA.
November 1995 - March 1999.
Pregnant women.
Singleton pregnancies.
15-24 weeks’ gestation.
Euploid/Down’s karyotype only.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 21 cases.
Reference standard: amniocentesis.
Index and comparator tests Maternal age.
Second trimester urinary ß core fragment (Spot specimens of urine - 2-step sandwich
assay B120 monoclonal antibody)
Second trimester serum AFP.
Frozen serum samples tested for second trimester uE3 and free ßhCG (details of serum
testing methods not given)
Follow-up 100% karyotyping.
Aim of study To compare Down’s syndrome screening efficiency of elevated maternal urine level of
beta core fragment with that of a traditional serum triple test
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
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Bahado-Singh 1999a (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results.
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Bahado-Singh 2000
Clinical features and settings High-risk referral for invasive testing.
Participants 1016 participants.
USA.
May 1995 - June 1998.
Singleton pregnancies.
Pregnant women.
Mean age 37.1 years (19.3-46 years).
14-24 weeks’ gestation.
Euploid or Down’s pregnancies only.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 23 cases.
Reference standard: amniocentesis.
Index and comparator tests Second trimester urinary hyperglycosylated hCG (Specific monoclonal antibody devel-
oped. 2-step enzyme immunometric assay standardised for creatinine levels)
Follow-up 100% karyotyping.
Aim of study To evaluate the measurement of levels of urine hyperglycosylated hCG in conjunction
with ultrasound biometry for Down’s syndrome risk prediction in an at risk group
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Bahado-Singh 2000 (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results.
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Bahado-Singh 2000a
Clinical features and settings High-risk referral for invasive testing.
Participants 524 participants.
USA - single hospital.
August 1995 - April 1999.
Singleton pregnancies.
Pregnant women.
Mean age 36.6 years (SD 5.3 years) in those with Down’s detected and 37.0 years (SD
3.4 years) in those with euploid pregnancies
14-22 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 24 cases.
Reference standard: amniocentesis.
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Bahado-Singh 2000a (Continued)
Index and comparator tests Maternal age.
Second trimester serum hCG (IMX total β-hCG kit, Abbott Laboratories), uE3 (DSL-
1400 Ultra-sensitive unconjugated Estriol Radioimmunoassay kit) and AFP (IMX AFP
kit, Abbott Laboratories)
Second trimester urinary beta core fragment (Spot specimens of urine - 2-step sandwich
assay B120 monoclonal antibody)
Frozen samples tested for second trimester urinary hyperglycosylated hCG (Specific
monoclonal antibody developed. 2-step enzyme immunometric assay standardised for
creatinine levels)
Follow-up 100% karyotyping.
Aim of study To compare the concentration of hyperglycosylated human chorionic gonadotropin with
serum triple screen for second trimester Down’s syndrome detection
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results.
Index test results blinded?
All tests
Unclear Unclear if index test interpreted with knowl-
edge of reference standard results.
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
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Bahado-Singh 2000a (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given.
Canick 1995
Clinical features and settings Referral for termination of pregnancy, amniocentesis or routine examination
Participants 105 participants: 14 cases and 91 controls.
USA.
Dates not reported.
Singleton pregnancies.
Pregnant women.
15-21 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 14 cases.
Reference standard: karyotyping on termination of pregnancy or amniocentesis
Index and comparator tests Maternal age.
Frozen samples tested for:
second trimester urinary gonadotropin peptide (Triton UGP EIA assay, Alameda);
second trimester serum hCG (MAIAclone hCG assay, Serono-Baker Diagnostics, Allen-
town)
Follow-up No details given for any follow-up to birth. Reported that the fetal karyotype of control
samples was not always known but assumed that none were aneuploid pregnancies
Aim of study To assess whether urinary gonadotropin peptide is better than serum hCG as a second
trimester screening marker
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening and selective testing of
high-risk women as done in practice
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
No Not all women received a reference stan-
dard.
Differential verification avoided?
All tests
No Women had different reference standards.
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Canick 1995 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without
knowledge of index test results
Index test results blinded?
All tests
Unclear Unclear if index test interpreted without
knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cole 1997a
Clinical features and settings High-risk referral for invasive testing.
Participants 722 participants.
USA - single hospital.
August 1995 - May 1996.
Pregnant women.
Singleton pregnancy.
12-24 weeks’ gestation.
Study design Cohort study.
Target condition and reference standard(s) Down’s syndrome: 13 cases.
Reference standard: amniocentesis.
Index and comparator tests Second trimester urinary hCG free beta subunit (Immunoenzymometric assay with
autoantibody FBT11)
Follow-up 100% karyotyping.
Aim of study To evaluate use of second trimester urinary free beta-subunit for Down’s syndrome
screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Cole 1997a (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cole 1997b
Clinical features and settings High-risk referral for invasive testing.
Participants 492 participants.
USA - single hospital.
August 1995 - May 1996.
Pregnant women.
Singleton pregnancy.
12-24 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 12 cases.
Reference standard: amniocentesis.
Index and comparator tests Second trimester urinary hCG free beta subunit (B210 2-step sandwich assay)
Second trimester urinary total oestriol (radioimmunoassay, kit fromDiagnostics Products
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Cole 1997b (Continued)
Corporation, Los Angeles)
Follow-up 100% karyotyping.
Aim of study To evaluate use of urinary free beta core fragment combined with urinary total oestriol
for Down’s syndrome screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant popula-
tion.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if index test interpretedwithout knowl-
edge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Cole 1999b
Clinical features and settings High-risk referral for invasive testing.
Participants 1157 participants.
USA - 3 hospitals.
May 1995 - March 1998.
Pregnant women.
Singleton pregnancy.
11-22 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 23 cases.
Reference standards: amniocentesis or CVS.
Index and comparator tests Urinary hCG beta-core subunit (B210 2-step sandwich assay).
Urinary total oestriol (radioimmunoassay, kit by Diagnostic Products Corporation, Los
Angeles)
Follow-up 100% karyotyping.
Aim of study To evaluate use of urinary free beta-subunit for Down’s syndrome screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis or CVS.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
No Women had CVS or amniocentesis depending
on their stage of pregnancy
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
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Cole 1999b (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cuckle 1995b
Clinical features and settings High-risk referral for invasive testing and testing for bacterial analysis
Participants 315 participants.
UK.
Dates not specified.
Pregnant women: 24 cases undergoing invasive testing and 294 controls undergoing
testing for bacterial analysis
11-23 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 24 cases.
Reference standards: amniocentesis or CVS for cases and follow-up for controls
Index and comparator tests Urinary beta core fragment (Modified radioimmunoassay method)
Urinary total oestrogen (continuous flow reaction based on the Kuber method)
Follow-up No details given of methods of follow-up.
Aim of study To evaluate the use of multiple urinary markers rather than serum in order to screen for
Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as
done in practice.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women had a reference standard.
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Cuckle 1995b (Continued)
Differential verification avoided?
All tests
No Women had different reference standards.
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without
knowledge of index test results.
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Cuckle 1999
Clinical features and settings High-risk referral for invasive testing and routine screening
Participants 349 participants: 45 cases and 304 controls.
UK.
Dates not specified.
Pregnant women.
14-19 weeks’ gestation.
Study design Retrospective case-control study.
Target condition and reference standard(s) Down’s syndrome: 45 cases.
Reference standard: amniocentesis, CVS or follow-up to birth
Index and comparator tests Frozen samples tested for urinary hyperglycosylated hCG (Immunoassays by ’Cole’
method corrected for creatinine levels using Jaffes method)
Follow-up Details of follow-up not reported.
Aim of study To determine the distribution of hyperglycosylated hCG levels in pregnancies with
Down’s syndrome
Notes
Table of Methodological Quality
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Cuckle 1999 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation.
Acceptable reference standard?
All tests
Yes Amniocentesis, CVS or follow-up.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
No Women had different reference standards.
Incorporation avoided?
All tests
Yes Index tests did not form part of the refer-
ence standard.
Reference standard results blinded?
All tests
Yes Reference standard conducted before the
index test.
Index test results blinded?
All tests
Unclear Index test conducted after the reference
standard and no evidence of blinding
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cuckle 1999a
Clinical features and settings High-risk referral for invasive testing and routine screening
Participants 6730 participants.
USA, UK and other European countries -multicentre study.
Dates not reported.
Pregnant women.
14-19 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 39 cases.
Reference standard: amniocentesis, CVS or postnatal examination
Index and comparator tests Maternal urine beta core hCG (Chiron manual assay).
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Cuckle 1999a (Continued)
Follow-up Methods of follow-up not reported.
Aim of study A prospective evaluation of urine beta core hCG for Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as
done in practice.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard.
Differential verification avoided?
All tests
No Women had different reference standards.
Incorporation avoided?
All tests
Yes Index tests did not form part of the refer-
ence standard.
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test conductedwithout knowledge of
the reference standard
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Hsu 1999
Clinical features and settings High-risk referral for invasive testing.
Participants 474 participants: 69 cases and 405 controls.
Taiwan and UK.
Dates not specified.
Pregnant women.
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Hsu 1999 (Continued)
Median age cases 36.0 years (21-44 years), controls 34.5 years (23-43 years)
14-26 weeks’ gestation.
Study design Retrospective case-control study.
Target condition and reference standard(s) Down’s syndrome: 69 cases.
Reference standard: amniocentesis.
Index and comparator tests Maternal age.
Urinary beta core fragment (UGP) (UGF-EIA Toa kit).
Urinary free beta hCG (CIS immunoradiometric assay).
Urinary total oestriol (Orthoclinical diagnostics oestriol (total) II radioimmunoassay kit)
All adjusted for creatinine concentration.
Modelled to standardised population for England and Wales 1991-1994. Cases from
Taiwan
Follow-up 100% karyotyping.
Aim of study To investigate levels of urinary beta core fragment, free beta hCG and total oestriol in a
new large set of Down’s syndrome pregnancies
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if index test interpretedwithout knowl-
edge of reference standard results
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Hsu 1999 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Isozaki 1997
Clinical features and settings High-risk referral for invasive testing.
Participants 726 participants.
USA - single centre.
August 1995 - May 1996.
Pregnant women.
Mean age 35.4 years (SD 4.0 years) in mothers of Down’s syndrome babies and 37 years
(SD 4.3 years) in mothers of healthy babies
Singleton pregnancies.
12-24 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 13 cases.
Reference standard: amniocentesis.
Index and comparator tests Urinary beta core fragment (B210 monoclonal antibody, 2-step sandwich assay)
Follow-up 100% karyotyping.
Aim of study To present data for prospectively collected samples of urinary beta core fragment for
Down’s syndrome screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
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Isozaki 1997 (Continued)
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Palomaki 2004a
Clinical features and settings High-risk referral for invasive testing.
Participants 2,055 participants.
USA - multicentre study.
January 2001 - January 2003.
Pregnant women with mean age 38.9 years.
15-20 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 28 cases.
Reference standard: amniocentesis.
Index and comparator tests Urinary invasive trophoblastic antigen (ITA) (B207 (detection) and B152 (capture) anti-
hCG monoclonal antibodies)
Follow-up 100% karyotyping.
Aim of study To evaluate ITA as a potential marker for Down’s syndrome in the second trimester of
pregnancy
Notes Clean catch of random urine provided. Sent same day at 4 degrees Celcius on an ice
pack. Aliquoted into 1 mL plastic tubes. 1 urine aliquot shipped to lab for testing. Rest
stored at -70 degrees Celcius. Most samples assayed within 24 hours of reaching lab and
all within 48 hours. Anti-ITA antibody produced. Sample corrected for creatinine levels
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Palomaki 2004a (Continued)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk population as done
in practice
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Spencer 1996
Clinical features and settings High-risk referral for invasive testing.
Participants 429 participants: 29 cases and 400 controls.
UK.
Date not specified.
Pregnant women.
Singleton pregnancies.
14-24 (cases) and 9-22 (controls) weeks’ gestation.
Study design Case-control study.
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Spencer 1996 (Continued)
Target condition and reference standard(s) Down’s syndrome: 29 cases.
Reference standards: amniocentesis or CVS.
Index and comparator tests Urine free beta hCG (CIS immunoradiometric assay).
Urinary beta core fragment (Ciba Corning diagnostics UGP enzyme immunoassay)
Follow-up 100% karyotyping.
Aim of study To evaluate whether free beta hCG is elevated in the urine of pregnancies affected by
Down’s syndrome and investigate whether urine free beta hCG may be used as possible
screening markers
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis or CVS.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
No Women had different reference standards.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Wald 2003
Clinical features and settings Routine screening.
Participants 606 participants: 101 cases, 505 controls matched for gestation, duration of storage and
centre
UK and Austria - multicentre trial.
September 1996 - April 2000.
Pregnant women.
9-13 and 14-20 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 101 cases.
Reference standards: invasive testing (following second trimester screening) or follow-
up to birth
Index and comparator tests First trimesterNT (midsagittal section, optimal magnification of thickness of translucent
space between inner skin surface and fascia covering cervical spine (white black interface
(outer) - black white interface (inner), 41 models of ultrasound machine, 20 minutes
allotted scanning time)
First and second trimester serum AFP, hCG, uE3, PAPP-A, free beta hCG (time resolved
fluoroimmunoassay, AutoDELFIA)
First and second trimester inhibin A (Sandwich enzyme-linked immunosorbent assay,
Oxford Bio-innovation)
First and second trimester urinary beta core fragment, total hCG, ITA and free beta
hCG (ITA and beta core fragment, Quest diagnostics USA)
Follow-up Follow-up by: 1) Staff at local hospitals completed a study outcome form at, or just
after. delivery, 2) Study records of CVS, amniocentesis or karyotype at birth linked to
information from cytogenic laboratories, 3) Study records linked to records of cases
of Down’s syndrome from the National Down’s Syndrome Cytogenetic Register, 4)
Information obtained from local obstetrical outcome records, 5) Forms sent to all women
with a request to return details of the outcome of their pregnancy, 6) Individual searches
in respect of women whose outcomes of pregnancy had not been obtained by any of
the previous methods. 4% of women in the total cohort did not have a documented
outcome of pregnancy. Unclear if any of these women were included in this nested case-
control study
Aim of study To identify the most effective, safe and cost-effective strategy for antenatal screening for
Down’s syndrome using NT, maternal serum and urine markers in the first and second
trimesters of pregnancy and maternal age in various combinations
Notes Performance of screening assessed at 17 weeks’ gestation. Study tried to be non-interven-
tional in the first trimester - second trimester testing was aimed to be used as the basis
for any referral for invasive testing
Table of Methodological Quality
Item Authors’ judgement Description
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Wald 2003 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
No Women received different reference standards.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Serum testing conducted after reference standard and unclear if
interpreted without knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice.
Uninterpretable results reported?
All tests
Yes Rates of NT failure on average 9%. Pre-10 weeks’ gestation, >
33% failure rate, declined to 7% at 12 weeks
Withdrawals explained?
All tests
No No details of withdrawals given.
Weinans 2000
Clinical features and settings High-risk referral for invasive testing.
Participants 63 participants: 8 cases and 55 controls matched for gestational and maternal age, ma-
ternal weight, duration of storage and smoking history
The Netherlands - single hospital.
October 1997 to May 1999.
Pregnant women.
10-11 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 8 cases.
Reference standard: CVS.
Index and comparator tests Urinary hyperglycosylated hCG, (procedures previously described in Cole 1999a).
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Weinans 2000 (Continued)
Follow-up 100% karyotyping.
Aim of study To investigate the value of H-hCG measurements in very early pregnancy (prior to 12
weeks’ gestation)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
AFP: alpha-fetoprotein
ßhCG: beta human chorionic gonadotrophin
CVS: chorionic villus sampling
hCG: human chorionic gonadotrophin
ITA: invasive trophoblast antigen
NT: nuchal translucency
PAPP-A: Pregnancy-associated plasma protein A
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SD: standard deviation
uE3: unconjugated oestriol
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbas 1995 Unable to extract useful data.
Abdul-Hamid 2004 No Down’s syndrome pregnancies.
Abraha 1999 Unable to extract useful data.
Adekunle 1999 Unable to extract useful information.
Aitken 1993 Unable to extract useful data.
Aitken 1996a Fewer than 80% of pregnancies had gestational age confirmed by USS
Aitken 1996b Fewer than 80% of pregnancies had gestational age confirmed by USS
Akbas 2001 Less than 5 Down’s syndrome pregnancies.
Antona 1998 Likely fewer than 80% of pregnancies dated by USS.
Antsaklis 1999 Women screened at greater than 24 weeks’ gestation.
Ashwood 1987 Unable to extract useful data.
Asrani 2005 Review article.
Audibert 2001b Data were not relevant to this review - this study was not looking at urine tests for Down’s syndrome
screening
Axt-Fleidner 2006 Unable to extract useful data.
Azuma 2002 Unable to extract useful data.
Baghagho 2004 Unable to obtain paper.
Bahado-Singh 1995 USS markers greater than 14 weeks’ gestation.
Bahado-Singh 1996 USS markers greater than 14 weeks’ gestation.
Bahado-Singh 1999b USS markers greater than 14 weeks’ gestation.
Bahado-Singh 2002 USS markers greater than 14 weeks’ gestation.
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(Continued)
Bahado-Singh 2003 Review article.
Bar-Hava 2001 No Down’s pregnancies in study population.
Barkai 1996 No Down’s pregnancies in study population.
Barnabei 1995 No Down’s pregnancies in study population.
Bartels 1988 Unable to extract useful data.
Bartels 1993 No Down’s pregnancies in study population.
Barth 1991 Second trimester ultrasound study.
Baviera 2004 Unclear method of confirmation of gestational age.
Bazzett 1998 Male versus female fetuses.
Bellver 2005 No Down’s syndrome pregnancies in study.
Benn 1995 Less than 80% follow-up.
Benn 1996 Less than 80% follow-up.
Benn 1997 No Down’s pregnancies in study population.
Benn 1998 Less than 80% follow-up.
Benn 2001 Statistical modelling (computer simulation).
Benn 2002 Modelled data.
Benn 2003a Less than 80% of pregnancies dated by USS.
Benn 2003b Editorial.
Benn 2005a No Down’s pregnancies included.
Benn 2005b Mathematical model.
Berry 1995 Less than 80% of pregnancies USS dated.
Berry 1997 Less than 80% of pregnancies USS dated.
Bersinger 1994 Gestational age not USS estimated.
Bersinger 2000 Unable to extract useful data.
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Bersinger 2001 No Down’s syndrome pregnancies in study population.
Bersinger 2003 Unable to extract useful data.
Bersinger 2004 No Down’s syndrome pregnancies in study population.
Bersinger 2005 No Down’s syndrome pregnancies in study population.
Biggio 2004 Cost-effectiveness analysis.
Bindra 2002 Review article.
Blundell 1999 Unable to extract useful data.
Boots 1989 Population risk factor calculations.
Borruto 2002 Unable to extract useful data.
Boue 1990 Review article.
Bradley 1994 Screen-negative population gestations not confirmed by ultrasound
Braithwaite 1996 Review article.
Brambati 1995 USS screening inclusive of women greater than 14 weeks’ gestation
Brambati 1996 Review article.
Brizot 1995a Unable to extract useful data.
Brizot 1995b Unable to extract useful data.
Brizzi 1989b Second trimester ultrasound.
Brock 1990 Unable to extract useful data.
Campogrande 2001 Unable to extract useful data.
Canick 1988 Unable to extract useful data.
Canick 1995b Unable to extract useful data.
Canini 2002 No Down’s syndrome pregnancies in study population.
Cans 1998 Second trimester ultrasound.
Carreras 1991 Second trimester ultrasound.
Chen 1999 Review article.
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Chen 2002 No Down’s syndrome pregnancies in study population.
Chen 2004 Less than 5 Down’s cases in study population.
Chen 2005 Unable to extract useful data.
Cheng 1993 Likely that fewer than 80% of gestational age confirmed by USS
Cheng 1999 Case series. No Down’s syndrome pregnancies in study population
Cheng 2004a No Down’s syndrome pregnancies in study population.
Cheng 2004b No Down’s syndrome pregnancies in study population.
Chitayat 2002 Less than 5 Down’s cases in study population.
Christiansen 2002 Unable to extract useful data.
Christiansen 2007 Unable to extract useful data.
Chung 2000 Less than 5 Down’s syndrome pregnancies in study population.
CNGOF 1996 Unable to obtain translation.
Cole 1996 Review article.
Comas 2001 USS at greater than 14 weeks.
Comas 2002a USS at greater than 14 weeks.
Comas 2002b USS at greater than 14 weeks.
Comstock 2006 Unable to extract useful data.
Conde-Agudelo 1998 Review article.
Crossley 1991 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1993 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1996 No Down’s syndrome pregnancies in study population.
Crossley 2002a Adjustment factors for smokers.
Cuckle 1984 Gestational age not confirmed by USS.
Cuckle 1987a Gestational age not confirmed by USS.
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Cuckle 1987b No gestational age limits given.
Cuckle 1990 Paper presenting adjustment factors.
Cuckle 1996 Data modelled on 4 meta-analysed studies.
Cuckle 1999b Unable to extract useful data.
Cuckle 1999c Review article.
Cullen 1990 Abnormal scans only in study population.
Cusick 2004 Less than 5 Down’s syndrome pregnancies in study population.
D’Ottavio 1997 Second trimester USS.
Dancoine 2001 No Down’s syndrome pregnancies in study population.
De Biasio 2000 Unable to extract useful information.
De Biasio, 1999 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Biasio, 2001 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Graaf 1991 Unable to extract useful data.
De Graaf 1999 Modelled data.
DeVore 2001 Second trimester ultrasound.
Dickerson 1994 Comment.
Dimaio 1987 Gestational age by USS only in screen-positive population.
Doran 1986 Ultrasound confirmation of gestational age performed in screen-positive women only
Drugan 1996a Second trimester ultrasound.
Drugan 1996b Unable to extract useful data.
Drysdale 2002 Fewer than 5 Down’s syndrome pregnancies in population.
Ebell 1999 Review article.
Economides 1998 Unable to extract useful data.
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Erickson 2004 No Down’s syndrome pregnancies in population.
Evans 1996 No Down’s syndrome pregnancies in population.
Falcon 2005 Unable to extract useful data.
Falcon 2006 Unable to extract useful data.
Ford 1998 Audit.
Frishman 1997 No Down’s syndrome pregnancies in population.
Fukada 2000 Unable to extract useful data.
Ghidini 1998 Comparison of male versus female fetuses.
Goldie 1995 Fewer than 80% of study population had gestational age confirmed by USS
Gonçalves 2004 Greater than 14 weeks USS screening.
Goodburn 1994 Likely that fewer than 80% of pregnancies had gestational age estimated by USS
Grozdea 2002 Unable to extract useful data.
Gyselaers 2004a Less than 80% follow-up.
Gyselaers 2004b Less than 80% follow-up.
Gyselaers 2006a Unaffected pregnancies only.
Gyselaers 2006b Unable to extract useful data.
Hackshaw 1995 No Down’s syndrome pregnancies in population.
Hackshaw 2001 No Down’s syndrome pregnancies in population
Haddow 1992 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Hafner 1995 Less than 5 Down’s pregnancies in study population.
Hallahan 1998 Gestational age greater than 24 weeks.
Harrison 2006 Less than 80% of pregnancies had gestational age confirmed by USS
Harry 2006 Editorial.
Hayashi 1995 Unable to extract useful data.
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Hayashi 1996 Less than 5 Down’s pregnancies in study population.
Heikkila 1997 Fewer than 80% of pregnancies had gestational age confirmed by USS
Heinonen 1996 No Down’s syndrome pregnancies in population.
Herman 2000 No Down’s syndrome pregnancies in study population.
Herman 2003 Correlation between markers, not evaluation of screening tests
Herrou 1992 Unable to extract useful data.
Hershey 1985 Gestation unclear.
Hershey 1986 Gestation based on LMP.
Hewitt 1993 Unable to extract useful data.
Hogdall 1992 Unclear method of determination of gestational age. Unable to extract useful data
Hong Kong Practitioner 2001 CME.
Howe 2000 Second trimester USS.
Hsiao 1991 Unable to obtain translation.
Hsieh 1999 No Down’s syndrome pregnancies in study population.
Hsu 1997b Adjustment factors.
Hsu 1998a No Down’s syndrome pregnancies in study population.
Hsu 1999b No Down’s pregnancies.
Huang 2003 No Down’s syndrome pregnancies in study population.
Huggon 2004 Study of cardiac function in pregnancies with normal and abnormal NT results
Hui 2003 No Down’s syndrome pregnancies in population.
Hui 2005 No Down’s syndrome pregnancies in population.
Hultén 2004 Editorial/commentary.
Hung 2003 Modelling.
Hurley 1993 Unable to extract useful data.
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Huttly 2004 No Down’s syndrome pregnancies in population.
Hwa 2004 Less than 5 Down’s pregnancies in population.
Iles 1996 Review.
Ind 1994 Unable to extract useful data.
Jean-Pierre 2005 Review article.
Johnson 1991 Gestatiojnal age estimated by USS in fewer than 80% of cases
Johnson 1993 Normal pregnancies only.
Jorgensen 1999 Gestation greater than 14 weeks for USS.
Josefsson 1998 No Down’s syndrome pregnancies in study population.
Jou 2001 Less than 5 Down’s syndrome pregnancies in study population.
Kagan 2006 Screen-positive pregnancies only.
Kautzmann 1995 Fewer than 80% pregnancies had gestational age estimated by USS
Keith 1992 Summary article.
Kelekci 2004 Less than 5 Down’s syndrome pregnancies in population.
Kellner 1995a Less than 5 Down’s syndrome pregnancies in population.
Kellner 1995b Less than 80% follow-up. Unable to ascertain proportion of population with gestational age con-
firmed by USS
Kellner 1997 Assumption of normal karyotype without reference standard in significant proportion of control
pregnancies
Knight 1990 Review article.
Knight 2001 Validation of a specific assay.
Knight 2005 Less than 80% of pregnancies had gestational age confirmed by USS
Koos 2006 Review article.
Kornman 1996 Less than 5 Down’s syndrome pregnancies in population.
Kornman 1997 Unable to extract useful information.
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Kramer 1998 No Down’s syndrome pregnancies in study population.
Krantz 1996 Modelled data.
Krantz 2005 Adjustment factor.
Kulch 1993 No Down’s cases in population.
Lai 1998 Modelled population.
Lai 2003 No Down’s syndrome pregnancies in study population.
Laigaard 2006a Unable to extract useful data.
Laigaard 2006b Simulation.
Lam 1997 Unable to extract useful data.
Lam 1998 Fewer than 80% pregnancies had gestational age estimated by USS
Lam 1999a No Down’s syndrome pregnancies in population.
Lam 1999b Unable to extract useful data.
Lam 2000 Study of women’s decisions about screening.
Lam 2001 Male versus female fetuses.
Lambert-Messerlian 1996 Fewer than 80% of pregnancies USS dated.
Lambert-Messerlian 1998 Unable to extract useful data.
Lehavi 2005 Down’s syndrome pregnancies only.
Leung 2006 Unable to separate twins from singletons therefore unable to extract useful data
Leymarie 1993 Appears to be a review article (French).
Li 1998 Unable to obtain translation.
Li 1999 Unable to obtain translation.
Liao 1997 Unable to obtain translation.
Liao 2001 Unable to extract useful data.
Lim 2002 Second trimester ultrasound.
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Lippman 1987 Editorial.
Liu 2003 Unable to obtain translation.
Lustig 1988 Gestational age by LMP only.
MacDonald 1991 Fewer than 80% of gestational ages estimated by USS.
Macintosh 1994 Unable to extract useful data.
Macintosh 1997 Unable to extract useful data.
Macri 1994 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Macri 1996 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Malone 1998 Review article.
Malone 2003 Review article.
Mangione 2001 Abnormal screening results only.
Maymon 2001a No Down’s syndrome pregnancies in study population.
Maymon 2001b No normal test results included therefore unable to extract meaningful data
Maymon 2002 No Down’s syndrome pregnancies in study population.
Maymon 2004 No Down’s syndrome pregnancies in study population.
Maymon 2005 Modelled data.
McDuffie 1996 USS dating on screen-positive women only.
Meier 2002 Observed versus expected cases of Down’s syndrome in a population
Merkatz 1984 Gestational age not confirmed by USS.
Merz 2005 Editorial.
Metzenbauer 2001 Normal pregnancies only.
Metzenbauer 2002 Unable to extract useful data.
Mikic 1999 No Down’s syndrome pregnancies in study population.
Miller 1991 Unable to extract useful data.
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Milunsky 1989 Fewer than 80% gestational age estimated by USS.
Milunsky 1996 Fewer than 80% gestational age estimated by USS.
Minobe 2002 Gestational age greater than specified limits.
Miyamura 1999 Unable to extract useful data.
Moghadam 1998 Unable to extract useful data.
Monni 2000 Less than 5 Down’s syndrome pregnancies.
Monni 2002 Review article.
Mooney 1994 Greater than 24 weeks’ gestation.
Muller 1994 No Down’s syndrome pregnancies in study population.
Muller 1996b Unable to extract useful data.
Muller 1999 Unable to extract useful data.
Muller 2002a Getstional age greater than 24 weeks.
Muller 2002b Unable to extract meaningful data - unable to separate double and triple test data
Muller 2003 No Down’s syndrome pregnancies in study population.
Murta 2002 Unable to extract useful data.
Musone 2000 Unable to extract useful data.
Musto 1986 Fewer than 80% USS dated.
Myrick 1990 Unable to extract useful data.
Neveux 1996a No Down’s syndrome pregnancies in population.
Neveux 1996b Unable to extract useful data.
Ng 2004 Unable to extract useful data.
Nicolaides 1992 Study of outcomes of abnormal NT results.
Nicolaides 2000 Review article.
Nicolaides 2004 Review article.
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Nicolaides 2005a Unable to obtain translation - appears to be a review article
Nicolaides 2005b Unable to obtain translation - appears to be a review article
Nicolaides 2005c Unable to obtain translation - appears to be a review article
Nicolaides 2005d Unable to obtain translation - appears to be a review article
Nicolaides 2005e Unable to obtain translation - appears to be a review article
Nicolaides 2005f Review article.
Niemimaa 2001 No Down’s pregnancies in study population.
Niemimaa 2002 No Down’s syndrome pregnancies in population.
Niemimaa 2003 No Down’s syndrome pregnancies in population.
Noble 1997 Unable to extract useful data.
Norgaard-Pedersen 1990 Less than 80% of gestational ages confirmed by USS.
Norton 1992 Unable to extract useful data.
O’Brien 1997a No Down’s syndrome pregnancies in population.
O’Brien 1997b No Down’s syndrome pregnancies in population.
Odibo 2004 Gestational age greater than 14 weeks in USS population.
Ognibene 1999 Unable to extract useful data.
Olajide 1989 Unable to extract useful data.
Onda 1996 Unable to extract useful data.
Onda 1998 Unable to extract useful data.
Onda 2000 Less than 80% follow-up.
Orlandi 2002 No Down’s syndrome pregnancies in study population.
Palka 1998 Twin data used in calculation of the median.
Palomaki 1989 Fewer than 80% USS dated.
Palomaki 1993 No Down’s syndrome pregnancies in population.
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Palomaki 1994 No Down’s syndrome pregnancies in population.
Palomaki 1996 Meta-analysis.
Palomaki 2005 Unable to extract meaningful data.
Panburana 2001 Less than 5 Down’s syndrome pregnancies in population.
Pandya 1994 Study of outcomes of abnormal NT results.
Pandya 1995 Review article.
Paul 2001 Unable to extract useful data.
Peralta 2005 Unable to extract useful data.
Perenc 1998 No Down’s syndrome pregnancies in study population.
Perheentupa 2002 No Down’s syndrome pregnancies in population.
Perona 1998 Smokers versus non smokers.
Petervari 2000 Unable to extract useful data.
Petrocik 1989 Likely fewer than 80% USS dated.
Phillips 1992 Gestational age confirmed by USS in less than 80% of population
Phillips 1993 Gestational age confirmed by USS in less than 80% of population
Pinette 2003 Women screened prior to recruitment.
Platt 2004 Unable to extract useful data.
Podobnik 1995 Abnormal results only.
Prefumo 2002 Comparison of prevalence and prediction.
Prefumo 2004 Comparison of a marker in women of different ethnic origins.
Price 1998 Unable to extract useful data.
Páez 2004 Unable to obtain translation.
Raty 2000 No Down’s syndrome pregnancies in population.
Rembouskos 2004 Unable to extract useful data.
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(Continued)
Ren 1992 Review article.
Renier 1998 Method of ascertainment of gestational age unclear. Twin gestations included in general population
Resta 1990 Second trimester USS.
Reynders 1997 Fewer than 5 Down’s cases.
Reynolds 1989 Explanation of mathematical techniques.
Reynolds 1999 Unable to extract useful data.
Ribbert 1996 No Down’s syndrome pregnancies in study population.
Rice 2005 Down’s syndrome pregnancies excluded from study.
Rich 1991 Unable to extract useful data.
Roberts 1995 No Down’s syndrome pregnancies in study population.
Robertson 1991 Editorial.
Rode 2003 No Down’s pregnancies.
Ronge 2006 Editorial - summary of FASTER trial results.
Rose 1995 Review article.
Ross 1997 Review article.
Rotmensch 1996 Unable to extract useful data.
Rotmensch 1999 No Down’s syndrome pregnancies in study population.
Rozenberg 2006 USS greater than 14 weeks’ gestation.
Rudnicka 2002 No Down’s syndrome pregnancies in population.
Ryall 1992 Unable to determine method of confirmation of gestational age
Ryall 2001 High-risk results only included (i.e. no screen-negative group for comparison)
Räty 2002 No Down’s pregnancies in population.
Sabriá 2002 Unable to ascertain how numbers calculated and from which populations
Sacchini 2003 Unable to extract useful data.
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(Continued)
Saller 1997 Down’s syndrome secondary to Robertsonian translocation only. No controls
Salomon 2001 No Down’s syndrome pregnancies in population.
Salonen 1997 Fewer than 80% had gestational age estimated by USS.
Saltvedt 2005 Gestation greater than 14 weeks for nuchal scanning.
Saridogan 1996 Down’s syndrome and Edward’s syndrome affected pregnancies only
Savoldelli 1993 Unable to extract useful data.
Schiott 2006 Unable to extract useful data.
Schuchter 1998 No Down’s pregnancies in study population.
Scott 1995 Less than 5 Down’s syndrome pregnancies in study population.
Seeds 1990 Review article.
Seki 1995 No Down’s syndrome pregnancies in study population.
Shenhav 2003 No Down’s syndrome pregnancies.
Shintaku 1989 Unable to extract useful data.
Shulman 2003 No Down’s syndrome pregnancies in population.
Simon-Bouy 1999 Review article.
Simpson 1986 Gestational age confirmed by USS in less than 80% of population
Smith 1990 Analysis of screen-positive results.
Smith 1996 Review/meta-analysis.
Smith 1999 Unable to extract useful data.
Smith-Bindman 2001 Meta-analysis of second trimester ultrasound markers.
Smith-Bindman 2003 Population study, not examining DTA.
Snijders 1995 Study of prevalence, not screening.
Snijders 1999 Study of prevalence, not screening.
Soergel 2006 Less than 80% follow-up.
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(Continued)
Sokol 1998 Observation of Down’s prevalence stratified by age.
Sonek 2003 Editorial.
Spencer 1985 Fewer than 80% USS dated.
Spencer 1991a Likely fewer than 80% USS dated.
Spencer 1991b Unable to extract useful data.
Spencer 1992 Unable to extract useful data.
Spencer 1993a Fewer than 80% USS dated.
Spencer 1993b No Down’s pregnancies in study population.
Spencer 1993c Unable to extract useful data.
Spencer 1993d Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1993e Unable to extract useful data.
Spencer 1995 No Down’s pregnancies in population.
Spencer 1996a Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1997 Statistical modelling, aneuploid pregnancies only in study population
Spencer 1998a No Down’s pregnancies in population.
Spencer 1998b Unable to extract useful data.
Spencer 1999a Review.
Spencer 1999b Statistical methods paper.
Spencer 2000a Examination of median shifts rather than an evaluation of screening
Spencer 2000b No Down’s syndrome pregnancies in population.
Spencer 2000c No Down’s syndrome pregnancies in population.
Spencer 2000d No Down’s cases.
Spencer 2000e Male versus female fetuses.
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(Continued)
Spencer 2000f No Down’s cases in population.
Spencer 2000g No Down’s pregnancies in population.
Spencer 2000h No Down’s pregnancies in population.
Spencer 2000i Comparsison of fetal sex.
Spencer 2001 No Down’s syndrome pregnancies in population.
Spencer 2001a Unable to extract useful data.
Spencer 2001b Unable to extract useful data.
Spencer 2001c Unable to extract useful data.
Spencer 2001d No Down’s syndrome pregnancies in population.
Spencer 2002a No Down’s pregnancies.
Spencer 2002b Risk validation study.
Spencer 2002c No Down’s syndrome pregnancies in population.
Spencer 2002d Demonstration of median changes with time, rather than evaluation of screening
Spencer 2003a No Down’s pregnancies in population.
Spencer 2003b No Down’s pregnancies in population.
Spencer 2003c Calculation of weight correction factor.
Spencer 2003d Fewer than 5 Down’s syndrome pregnancies.
Spencer 2004 Calculation of smoking correction factor.
Spencer 2005a No Down’s pregnancies.
Spencer 2005b No Down’s pregnancies.
Spencer 2005c Comparison of 2 different assays - not actual screening evaluation
Spong 1999 Comparison of male and female fetuses.
Stevens 1998 Literature review.
Stoll 1992 Review article.
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(Continued)
Su 2002a Unable to extract useful data.
Suchet 1995 Review article.
Suchy 1990 Unable to ascertain method of confirmation of gestational age
Summers 2003a Fewer than 80% had gestational age estimated by USS.
Summers 2003b No Down’s syndrome pregnancies in study population.
Suntharasaj 2005 Examination of inter-observer variation in NT scanning.
Sutton 2004 Unable to extract useful data.
Suzuki 1998 Unable to extract useful data.
Tabor 1987 Geststional age not confirmed by USS.
Tanski 1999 Information on screen-positive pregnancies only.
Thilaganathan 1998 No Down’s syndrome pregnancies in study population.
Thilaganathan 1999 Editorial.
Tislaric 2002 No Down’s syndrome pregnancies in population.
Torok 1997 Unable to extract useful data.
Tsai 2001 Less than 5 Down’s syndrome pregnancies in study population.
Valerio 1996 Fewer than 80% pregnancies had gestational age estimated by USS
Van Blerk 1992 Unable to extract useful data.
Van Heesch, 2006 No Down’s syndrome pregnancies in study population. Software comparison study
Van Lith 1991 Unable to extract useful data.
Van Lith 1993 Unable to extract useful data.
Van Lith 1994 Unable to extract useful data.
Veress 1986 Unable to extract useful data.
Veress 1988 Unable to extract useful data.
Vintzileos 2003 Second trimester USS.
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(Continued)
Wald 1988a Less than 80% had gestational age confirmed by ultrasound.
Wald 1988b Gestational age not confirmed by USS.
Wald 1991 No Down’s pregnancies in study.
Wald 1992a Less than 80% had gestational age confirmed by ultrasound.
Wald 1992b No Down’s pregnancies in study.
Wald 1992c No Down’s pregnancies in study.
Wald 1993 Fewer than 80% had gestational age estimated by USS
Wald 1994a No Down’s syndrome pregnancies in population.
Wald 1994b Review article.
Wald 1996a No Down’s pregnancies.
Wald 1996b Fewer than 80% had gestational age estimated by USS
Wald 1996d No Down’s syndrome pregnancies in population.
Wald 1996e Gestational age greater than 24 weeks.
Wald 1997 Data modelled on 3 separate populations of women.
Wald 1998 Unable to extract useful data.
Wald 1999a Unable to extract useful data.
Wald 1999b Gestational age not confirmed by USS.
Wald 1999c No Down’s syndrome pregnancies.
Wald 1999d Modelled on several studies, some of which have no USS dating
Wald 2003b No cases.
Wald 2003c Less than 80% had gestational age confirmed by USS.
Wald 2006 Modelled on SURRUS data.
Wallace 1994 Unable to extract useful data.
Wallace 1997 No Down’s syndrome pregnancies in study population.
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(Continued)
Ward 2005 Review article.
Watt 1996a No Downs syndrome pregnancies in study population.
Watt 1996b No Down’s syndrome pregnancies in study population.
Weinans 2001 Unable to extract useful data.
Weinans 2004 Study of women’s views on screening.
Welborn 1994 Abnormal results only (cystic hygroma).
Wenstrom 1993 Less than 80% of pregnancies had gestational age confirmed by USS
Wenstrom 1995a Adjustment factors.
Wenstrom 1995b Less than 80% of pregnancies had gestational age confirmed by USS
Whitlow 1998a Unable to extract useful data.
Whitlow 1998b Unable to extract useful data.
Whitlow 1999 Unable to extract useful data.
Williamson 1994 Fewer than 80% had gestational age estimated by USS.
Wilson 2000 Review.
Wojdemann 2001 No Down’s syndrome pregnancies in study population.
Wong 2003 Less than 5 Down’s syndrome pregnancies in population.
Wright 2006 Mathematical model.
Yagel 1998 Second trimester USS.
Yamamoto 2001a Unable to extract useful data.
Yamamoto 2001b Method of determination of gestational age unclear.
Yamamoto 2001c Unable to extract useful data.
Yaron 2001 Male versus female fetuses.
Ye 1995 Unable to obtain translation.
Yoshida 2000 Fewer than 80% pregnancies had gestational age estimated by USS
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(Continued)
Zeitune 1991 Only aneuploid pregnancies included in study.
Zelop 2005 No Down’s cases in population.
Zhao 1998 Unable to obtain translation.
Zoppi 2003 Inappropriate study design.
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Betacore, 1st trimester urine test,
5% FPR
1 516
2 Betacore, 2nd trimester urine
test, 5% FPR
6 9613
3 Betacore, 2nd trimester urine
test, cutpoint mixed
7 10124
4 Gonadotropin, 2nd trimester
urine test, risk 1:100
1 105
5 Gonadotropin, 2nd trimester
urine test, risk 1:384
1 105
6 Gonadotropin, 2nd trimester
urine test, 95% percentile
1 105
7 ITA, 1st trimester urine test, 5%
FPR
2 579
8 ITA, 2nd trimester urine test,
3.74MoM
1 2051
9 ITA, 2nd trimester urine test,
5% FPR
3 2748
10 Total hCG, 1st trimester urine
test, 5% FPR
1 516
11 Total hCG, 2nd trimester urine
test, 5% FPR
1 390
12 Free ßhCG, 1st trimester urine
test, 5% FPR
1 516
13 Free ßhCG, 2nd trimester
urine test, 5% FPR
3 1517
14 Oestriol, 2nd trimester urine
test, 5% FPR
2 1472
15 Betacore to oestriol ratio, 2nd
trimester urine test, 5% FPR
2 1649
16 Betacore and oestriol, 2nd
trimester 5% FPR
1 315
17 AFP and ITA, 2nd trimester
urine test, 3% FPR
1 524
18 AFP and ITA, 2nd trimester
urine test, 5% FPR
1 524
19 AFP and ITA, 2nd trimester
urine test,10% FPR
1 524
20 AFP and ITA, 2nd trimester
urine test, 15% FPR
1 524
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21 AFP, uE3 and ITA, 2nd
trimester urine test, 3% FPR
1 524
22 AFP, uE3 and ITA, 2nd
trimester urine test, 5% FPR
1 524
23 AFP, uE3 and ITA, 2nd
trimester urine test, 10% FPR
1 524
24 AFP, uE3 and ITA, 2nd
trimester urine test, 15% FPR
1 524
25 Age, betacore, 2nd trimester
urine test, 1% FPR
2 2083
26 Age, betacore, 2nd trimester
urine test, 3% FPR
2 2083
27 Age, betacore, 2nd trimester
urine test, 5% FPR
5 3419
28 Age, betacore, 2nd trimester
urine test, 10% FPR
1 926
29 Age, betacore, 2nd trimester
urine test, 15% FPR
1 953
30 Age, betacore, 2nd trimester
urine test, 20% FPR
1 926
31 Age, ITA, 2nd trimester urine
test, 5% FPR
1 1016
32 Age, oestriol, 2nd trimester
urine test, 5% FPR
1 474
33 Age, free ßhCG, 2nd trimester
urine test, 5% FPR
2 879
34 Age, betacore to oestriol ratio,
2nd trimester urine test, 1%
FPR
1 1157
35 Age, betacore to oestriol ratio,
2nd trimester urine test, 3%
FPR
1 1157
36 Age, betacore to oestriol ratio,
2nd trimester urine test, 5%
FPR
3 2088
37 Age, free ßhCG to oestriol
ratio, 2nd trimester urine test,
5% FPR
1 474
38 Age, oestriol and free ßhCG,
2nd trimester, 5% FPR
1 474
39 Age, betacore to free ßhCG
ratio, 2nd trimester, 5% FPR
1 474
40 Age, betacore and oestriol, 2nd
trimester 1% FPR
1 1157
41 Age, betacore and oestriol, 2nd
trimester, 3% FPR
1 1157
42 Age, betacore and oestriol, 2nd
trimester, 5% FPR
2 1631
43 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:10
1 356
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44 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:20
1 356
45 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:30
1 356
46 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:58
1 356
47 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:270
1 356
48 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:526
1 356
Test 1. Betacore, 1st trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 1 Betacore, 1st trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 9 22 77 408 0.10 [ 0.05, 0.19 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Betacore, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 2 Betacore, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 15 54 8 1080 0.65 [ 0.43, 0.84 ] 0.95 [ 0.94, 0.96 ]
Cuckle 1995b 19 15 5 276 0.79 [ 0.58, 0.93 ] 0.95 [ 0.92, 0.97 ]
Cuckle 1999a 9 329 30 6256 0.23 [ 0.11, 0.39 ] 0.95 [ 0.94, 0.96 ]
Isozaki 1997 8 35 5 674 0.62 [ 0.32, 0.86 ] 0.95 [ 0.93, 0.97 ]
Spencer 1996 6 19 23 357 0.21 [ 0.08, 0.40 ] 0.95 [ 0.92, 0.97 ]
Wald 2003 9 16 56 309 0.14 [ 0.07, 0.25 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Betacore, 2nd trimester urine test, cutpoint mixed.
Review: Urine tests for Down’s syndrome screening
Test: 3 Betacore, 2nd trimester urine test, cutpoint mixed
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998 11 16 7 477 0.61 [ 0.36, 0.83 ] 0.97 [ 0.95, 0.98 ]
Cole 1999b 15 54 8 1080 0.65 [ 0.43, 0.84 ] 0.95 [ 0.94, 0.96 ]
Cuckle 1995b 19 15 5 276 0.79 [ 0.58, 0.93 ] 0.95 [ 0.92, 0.97 ]
Cuckle 1999a 9 329 30 6256 0.23 [ 0.11, 0.39 ] 0.95 [ 0.94, 0.96 ]
Isozaki 1997 8 35 5 674 0.62 [ 0.32, 0.86 ] 0.95 [ 0.93, 0.97 ]
Spencer 1996 6 19 23 357 0.21 [ 0.08, 0.40 ] 0.95 [ 0.92, 0.97 ]
Wald 2003 9 16 56 309 0.14 [ 0.07, 0.25 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Gonadotropin, 2nd trimester urine test, risk 1:100.
Review: Urine tests for Down’s syndrome screening
Test: 4 Gonadotropin, 2nd trimester urine test, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Canick 1995 11 2 3 89 0.79 [ 0.49, 0.95 ] 0.98 [ 0.92, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Gonadotropin, 2nd trimester urine test, risk 1:384.
Review: Urine tests for Down’s syndrome screening
Test: 5 Gonadotropin, 2nd trimester urine test, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Canick 1995 13 5 1 86 0.93 [ 0.66, 1.00 ] 0.95 [ 0.88, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Gonadotropin, 2nd trimester urine test, 95% percentile.
Review: Urine tests for Down’s syndrome screening
Test: 6 Gonadotropin, 2nd trimester urine test, 95% percentile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Canick 1995 12 5 2 86 0.86 [ 0.57, 0.98 ] 0.95 [ 0.88, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. ITA, 1st trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 7 ITA, 1st trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 5 22 81 408 0.06 [ 0.02, 0.13 ] 0.95 [ 0.92, 0.97 ]
Weinans 2000 3 3 5 52 0.38 [ 0.09, 0.76 ] 0.95 [ 0.85, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. ITA, 2nd trimester urine test, 3.74MoM.
Review: Urine tests for Down’s syndrome screening
Test: 8 ITA, 2nd trimester urine test, 3.74MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2004a 15 101 13 1922 0.54 [ 0.34, 0.72 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 9. ITA, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 9 ITA, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cuckle 1999 17 13 21 256 0.45 [ 0.29, 0.62 ] 0.95 [ 0.92, 0.97 ]
Palomaki 2004a 13 49 15 1974 0.46 [ 0.28, 0.66 ] 0.98 [ 0.97, 0.98 ]
Wald 2003 26 16 39 309 0.40 [ 0.28, 0.53 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Total hCG, 1st trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 10 Total hCG, 1st trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 15 22 71 408 0.17 [ 0.10, 0.27 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 11. Total hCG, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 11 Total hCG, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 20 16 45 309 0.31 [ 0.20, 0.43 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Free ßhCG, 1st trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 12 Free hCG, 1st trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 4 22 82 408 0.05 [ 0.01, 0.11 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 13. Free ßhCG, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 13 Free hCG, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1997a 7 35 6 674 0.54 [ 0.25, 0.81 ] 0.95 [ 0.93, 0.97 ]
Spencer 1996 12 19 17 357 0.41 [ 0.24, 0.61 ] 0.95 [ 0.92, 0.97 ]
Wald 2003 8 16 57 309 0.12 [ 0.05, 0.23 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. Oestriol, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 14 Oestriol, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 3 54 20 1080 0.13 [ 0.03, 0.34 ] 0.95 [ 0.94, 0.96 ]
Cuckle 1995b 8 15 16 276 0.33 [ 0.16, 0.55 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 15. Betacore to oestriol ratio, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 15 Betacore to oestriol ratio, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1997b 9 24 3 456 0.75 [ 0.43, 0.95 ] 0.95 [ 0.93, 0.97 ]
Cole 1999b 17 54 6 1080 0.74 [ 0.52, 0.90 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. Betacore and oestriol, 2nd trimester 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 16 Betacore and oestriol, 2nd trimester 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cuckle 1995b 20 15 4 276 0.83 [ 0.63, 0.95 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. AFP and ITA, 2nd trimester urine test, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 17 AFP and ITA, 2nd trimester urine test, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 16 15 8 485 0.67 [ 0.45, 0.84 ] 0.97 [ 0.95, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 18. AFP and ITA, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 18 AFP and ITA, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 19 25 5 475 0.79 [ 0.58, 0.93 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. AFP and ITA, 2nd trimester urine test,10% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 19 AFP and ITA, 2nd trimester urine test,10% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 21 50 3 450 0.88 [ 0.68, 0.97 ] 0.90 [ 0.87, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 20. AFP and ITA, 2nd trimester urine test, 15% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 20 AFP and ITA, 2nd trimester urine test, 15% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 22 75 2 425 0.92 [ 0.73, 0.99 ] 0.85 [ 0.82, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. AFP, uE3 and ITA, 2nd trimester urine test, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 21 AFP, uE3 and ITA, 2nd trimester urine test, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 18 15 6 485 0.75 [ 0.53, 0.90 ] 0.97 [ 0.95, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. AFP, uE3 and ITA, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 22 AFP, uE3 and ITA, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 19 25 5 475 0.79 [ 0.58, 0.93 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. AFP, uE3 and ITA, 2nd trimester urine test, 10% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 23 AFP, uE3 and ITA, 2nd trimester urine test, 10% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 22 50 2 450 0.92 [ 0.73, 0.99 ] 0.90 [ 0.87, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. AFP, uE3 and ITA, 2nd trimester urine test, 15% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 24 AFP, uE3 and ITA, 2nd trimester urine test, 15% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 22 75 2 425 0.92 [ 0.73, 0.99 ] 0.85 [ 0.82, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. Age, betacore, 2nd trimester urine test, 1% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 25 Age, betacore, 2nd trimester urine test, 1% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 6 9 15 896 0.29 [ 0.11, 0.52 ] 0.99 [ 0.98, 1.00 ]
Cole 1999b 7 11 16 1123 0.30 [ 0.13, 0.53 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 26. Age, betacore, 2nd trimester urine test, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 26 Age, betacore, 2nd trimester urine test, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 11 27 10 878 0.52 [ 0.30, 0.74 ] 0.97 [ 0.96, 0.98 ]
Cole 1999b 11 34 12 1100 0.48 [ 0.27, 0.69 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 27. Age, betacore, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 27 Age, betacore, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999 10 22 3 422 0.77 [ 0.46, 0.95 ] 0.95 [ 0.93, 0.97 ]
Bahado-Singh 1999a 13 30 8 875 0.62 [ 0.38, 0.82 ] 0.97 [ 0.95, 0.98 ]
Cole 1999b 15 54 8 1080 0.65 [ 0.43, 0.84 ] 0.95 [ 0.94, 0.96 ]
Hsu 1999 34 20 35 385 0.49 [ 0.37, 0.62 ] 0.95 [ 0.92, 0.97 ]
Spencer 1996 12 19 17 357 0.41 [ 0.24, 0.61 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. Age, betacore, 2nd trimester urine test, 10% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 28 Age, betacore, 2nd trimester urine test, 10% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 16 91 5 814 0.76 [ 0.53, 0.92 ] 0.90 [ 0.88, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. Age, betacore, 2nd trimester urine test, 15% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 29 Age, betacore, 2nd trimester urine test, 15% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 16 136 5 796 0.76 [ 0.53, 0.92 ] 0.85 [ 0.83, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 30. Age, betacore, 2nd trimester urine test, 20% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 30 Age, betacore, 2nd trimester urine test, 20% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 18 181 3 724 0.86 [ 0.64, 0.97 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 31. Age, ITA, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 31 Age, ITA, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000 16 50 7 943 0.70 [ 0.47, 0.87 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 32. Age, oestriol, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 32 Age, oestriol, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 34 20 35 385 0.49 [ 0.37, 0.62 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 33. Age, free ßhCG, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 33 Age, free hCG, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 39 20 30 385 0.57 [ 0.44, 0.68 ] 0.95 [ 0.92, 0.97 ]
Spencer 1996 17 19 12 357 0.59 [ 0.39, 0.76 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 34. Age, betacore to oestriol ratio, 2nd trimester urine test, 1% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 34 Age, betacore to oestriol ratio, 2nd trimester urine test, 1% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 5 11 18 1123 0.22 [ 0.07, 0.44 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. Age, betacore to oestriol ratio, 2nd trimester urine test, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 35 Age, betacore to oestriol ratio, 2nd trimester urine test, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 13 34 10 1100 0.57 [ 0.34, 0.77 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 36. Age, betacore to oestriol ratio, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 36 Age, betacore to oestriol ratio, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999 11 22 2 422 0.85 [ 0.55, 0.98 ] 0.95 [ 0.93, 0.97 ]
Cole 1999b 18 54 5 1080 0.78 [ 0.56, 0.93 ] 0.95 [ 0.94, 0.96 ]
Hsu 1999 40 20 29 385 0.58 [ 0.45, 0.70 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 37. Age, free ßhCG to oestriol ratio, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 37 Age, free hCG to oestriol ratio, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 44 20 25 385 0.64 [ 0.51, 0.75 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. Age, oestriol and free ßhCG, 2nd trimester, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 38 Age, oestriol and free hCG, 2nd trimester, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 47 20 22 385 0.68 [ 0.56, 0.79 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. Age, betacore to free ßhCG ratio, 2nd trimester, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 39 Age, betacore to free hCG ratio, 2nd trimester, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 46 20 23 385 0.67 [ 0.54, 0.78 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 40. Age, betacore and oestriol, 2nd trimester 1% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 40 Age, betacore and oestriol, 2nd trimester 1% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 9 11 14 1123 0.39 [ 0.20, 0.61 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 41. Age, betacore and oestriol, 2nd trimester, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 41 Age, betacore and oestriol, 2nd trimester, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 17 34 6 1100 0.74 [ 0.52, 0.90 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 42. Age, betacore and oestriol, 2nd trimester, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 42 Age, betacore and oestriol, 2nd trimester, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 19 54 4 1080 0.83 [ 0.61, 0.95 ] 0.95 [ 0.94, 0.96 ]
Hsu 1999 47 20 22 385 0.68 [ 0.56, 0.79 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 43. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:10.
Review: Urine tests for Down’s syndrome screening
Test: 43 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:10
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 4 4 6 342 0.40 [ 0.12, 0.74 ] 0.99 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 44. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:20.
Review: Urine tests for Down’s syndrome screening
Test: 44 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:20
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 5 6 5 340 0.50 [ 0.19, 0.81 ] 0.98 [ 0.96, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:30.
Review: Urine tests for Down’s syndrome screening
Test: 45 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:30
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 8 11 2 335 0.80 [ 0.44, 0.97 ] 0.97 [ 0.94, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 46. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:58.
Review: Urine tests for Down’s syndrome screening
Test: 46 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:58
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 9 16 1 330 0.90 [ 0.55, 1.00 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:270.
Review: Urine tests for Down’s syndrome screening
Test: 47 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:270
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 9 63 1 283 0.90 [ 0.55, 1.00 ] 0.82 [ 0.77, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 48. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:526.
Review: Urine tests for Down’s syndrome screening
Test: 48 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:526
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 10 97 0 249 1.00 [ 0.69, 1.00 ] 0.72 [ 0.67, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Direct comparisons of the diagnostic accuracy of five urine tests in combination with maternal age
Ratio of DORs (95%
CI); P values (studies)
Second trimester AFP
and ß-core fragment to
oestriol ratio, risk 1:58
Second
trimester ß-core frag-
ment and oestriol, 5%
FPR
Second trimester ITA,
5% FPR
Second
trimester ß-core frag-
ment to oestriol ratio,
5% FPR
Second
trimester ß-core frag-
ment and oestriol, 5%
FPR
-
Second trimester ITA,
5% FPR
- -
Second
trimester ß-core frag-
ment to oestriol ratio,
5% FPR
- 1.5 (0.7 to 3.0); P = 0.27
(K = 2)
Second trimester ß-
core fragment, 5% FPR
- 2.2 (1.1 to 4.5); P = 0.02
(K = 2)
- 1.5 (0.8 to 2.8); P = 0.21
(K = 3)
Direct comparisons were made using only data from studies that compared each pair of tests in the same population. Ratio of diagnostic
odds ratios (DOR)s were computed by division of the DOR for the test in the column by the DOR for the test in the row. If the
ratio of DORs is greater than one, then the diagnostic accuracy of the test in the column is higher than that of the test in the row;
if the ratio is less than one, the diagnostic accuracy of the test in the row is higher than that of the test in the column.
AFP: alpha-fetoprotein; CI: confidence interval; DORs: diagnostic odds ratio; FPR: false positive rate; ITA: invasive trophoblast
antigen
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Table 2. Indirect comparisons of the diagnostic accuracy of five urine tests in combination with maternal age
Ratio of
DOR (95% CI)
; P value
Second trimester
AFP and ß-
core fragment to
oestriol ratio, risk
1:58
Second trimester
ß-core fragment
and oestriol, 5%
FPR
Second trimester
ITA, 5% FPR
Second trimester
ß-core fragment
to oestriol ratio,
5% FPR
Studies 1 2 1 3
Studies DOR (95% CI) 186 (22, 1560) 50 (30 to 84) 43 (17 to 110) 38 (24 to 59)
Second
trimester ß-core
fragment and
oestriol, 5%
FPR
2 50 (30 to 84) 3.7 (0.4 to 33.0); P
= 0.24
Second
trimester ITA,
5% FPR
1 43 (17 to 110) 4.3 (0.4 to 44.0); P
= 0.22
1.2 (0.4 to 3.4); P
= 0.78
Second
trimester ß-core
fragment
to oestriol ratio,
5% FPR
3 38 (24 to 59) 4.9 (0.6 to 43.4); P
= 0.15
1.3 (0.7 to 2.6); P
= 0.41
1.1 (0.4 to 3.2); P
= 0.80
Second
trimester ß-core
fragment, 5%
FPR
5 25 (18 to 36) 7.3 (0.8 to 63.1); P
= 0.07
2.0 (1.1 to 3.7); P
= 0.03
1.7 (0.6 to 4.6); P
= 0.30
1.5 (0.8 to 2.6); P
= 0.18
Indirect comparisons were made using all available data. Ratio of diagnostic odds ratios (DOR)s were computed by division of the
DOR for the test in the column by the DOR for the test in the row. If the ratio of DORs is greater than one, then the diagnostic
accuracy of the test in the column is higher than that of the test in the row; if the ratio is less than one, the diagnostic accuracy of
the test in the row is higher than that of the test in the column.
AFP: alpha-fetoprotein; CI: confidence interval; DORs: diagnostic odds ratio; FPR: false positive rate; ITA: invasive trophoblast
antigen
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A P P E N D I C E S
Appendix 1. Search strategy
Database: Ovid MEDLINE
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 exp Pregnancy-Associated Plasma Protein-A/
4 pregnancy associated plasma protein a.mp.
5 papp-a.mp.
6 exp Chorionic Gonadotropin, beta Subunit, Human/
7 (b-hcg or bhcg).mp.
8 human chorionic gonadotropin.mp.
9 exp alpha-Fetoproteins/
10 alphafetoprotein$.mp.
11 alpha-fetoprotein$.mp.
12 afp.mp.
13 (unconjugated estriol or unconjugated oestriol).mp.
14 ue3.mp.
15 exp INHIBINS/
16 inhibin a.mp.
17 ultrasound.mp.
18 amniocentesis/
19 chorion$ vill$ sampling.mp.
20 Chorionic Villi-Sampling/
21 nasal bone.mp.
22 tricuspid regurgitation.mp.
23 ductus venosus.mp
24 marker$.mp.
25 screen$.mp.
26 detect$.mp.
27 accura$.mp.
28 predict$.mp.
29 ROC.mp.
30 ROC curve/
31 AUC.mp.
32 Area under curve/
33 exp false negative reactions/ or exp false positive reactions/
34 (false positive$ or false negative$).mp.
35 likelihood ratio$.mp.
36 sensitiv$.mp.
37 specific$.mp.
38 diagnos$.ti,ab.
39 “reproducibility of results”.mp.
40 reference value$.mp.
41 reference standard$.mp.
42 exp Down Syndrome/
43 downs syndrome.mp.
44 down syndrome.mp.
45 trisomy 21.mp.
46 Aneuploidy/
47 aneuploidy.mp.
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48 Mosaicism/
49 mosaicism.mp.
50 or/1-41
51 or/42-49
52 50 and 51
53 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
54 52 and 53
55 animal/ not (humans/ and animal/)
56 54 not 55
*******************************************************
EMBASE via Dialog Datastar
1. PRENATAL-DIAGNOSIS#.DE.
2. FETUS-ECHOGRAPHY#.DE.
3. PREGNANCY-ASSOCIATED-PLASMA-PROTEIN-A#.DE.
4. CHORIONIC-GONADOTROPIN-BETA-SUBUNIT#.DE.
5. HCG.AB.
6. PAPP.AB.
7. ALPHA-FETOPROTEIN#.DE.
8. AFP.AB.
9. ALPHA ADJ FETOPROTEIN$
10. ALPHAFETOPROTEIN$
11. BETA ADJ HUMAN ADJ CHORIONIC ADJ GONADOTROPIN
12. PREGNANCY ADJ ASSOCIATED ADJ PLASMA ADJ PROTEIN
13. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).TI.
14. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).AB.
15. UE3
16. INHIBIN-A#.DE.
17. INHIBIN ADJ A
18. ULTRASOUND
19. AMNIOCENTESIS
20. CHORION-VILLUS-SAMPLING.DE.
21. NASAL ADJ BONE
22. TRICUSPID ADJ REGURGITATION
23. DUCTUS ADJ VENOSUS
24. MARKER ORMARKERS
25. SCREEN OR SCREENING
26. DETECT OR DETECTING OR DETECTION
27. FALSE ADJ POSITIVE$
28. FALSE ADJ NEGATIVE$
29. SENSITIVITY OR SENSITIVE OR SENSITIVITIES
30. SPECIFICITY OR SPECIFICITIES
31. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).TI.
32. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).AB.
33. ROC.AB.
34. AUC.AB.
35. AREA-UNDER-THE-CURVE.DE.
36. ROC-CURVE.DE.
37. ACCURA$
38. PREDICT$
39. REPRODUCIBILITY.DE.
40. REFERENCE ADJ VALUE$
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41. REFERENCE-VALUE.DE.
42. REFERENCE ADJ STANDARD$
43. DOWN-SYNDROME#.DE.
44. DOWN ADJ SYNDROME OR DOWNS ADJ SYNDROME
45. TRISOMY ADJ ’21’
46. MOSAICISM
47. ANEUPLOIDY
48. ANTENATAL$ OR PRENATAL$ OR PREGNANCY OR PREGNANT OR TRIMESTER$ OR MATERNAL OR FETUS
OR FOETUS OR FOETAL OR FETAL
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19
OR 20 OR 21 Or 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR
37 OR 38 OR 39 OR 40 OR 41 OR 42
50. 43 OR 44 OR 45 OR 46 OR 47
51. 48 AND 49 AND 50
52. HUMAN=YES
53. 51 AND 52
ADJ = adjacent AB = abstract
TI = title $ = truncation symbol DE = descriptor (similar to MeSH)
*******************************************************
CINAHL via OVID
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 pregnancy associated plasma protein.mp.
4 papp$.ti,ab.
5 exp Gonadotropins, chorionic/
6 (b-hcg or bhcg).mp.
7 human chorionic gonadotropin.mp.
8 exp alpha-Fetoproteins/
9 alphafetoprotein$.mp.
10 alpha-fetoprotein$.mp.
11 afp.mp.
12 (unconjugated estriol or unconjugated oestriol).mp.
13 ue3.mp.
14 inhibin$.mp.
15 ultrasound.mp.
16 amniocentesis/
17 chorion$ vill$ sampling.mp.
18 Chorionic Villi-Sampling/
19 nasal bone.mp.
20 tricuspid regurgitation.mp.
21 ductus venosus.mp.
22 marker$.mp.
23 screen$.mp.
24 detect$.mp.
25 accura$.mp.
26 predict$.mp.
27 ROC.mp.
28 ROC curve/
29 AUC.mp.
30 “area under curve”.mp.
31 exp false negative reactions/ or exp false positive reactions/
32 (false positive$ or false negative$).mp.
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33 likelihood ratio$.mp.
34 sensitiv$.mp.
35 specific$.mp.
36 diagnos$.ti,ab.
37 “reproducibility of results”.mp.
38 reference value$.mp.
39 reference standard$.mp.
40 exp Down Syndrome/
41 downs syndrome.mp.
42 down syndrome.mp.
43 trisomy 21.mp.
44 aneuploidy.mp.
45 mosaicism.mp.
46 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
47 or/1-39
48 or/40-45
49 47 and 48 and 46
*******************************************************
Search terms and instructions for Biosis
The following search terms were entered separately in standard search box (select ‘Titles/subject/abstract’ from the drop-down box on
the right of the search box).
1. “reference standard*”
2. “reference value*”
3. “reproducibility of results”
4. diagnos*
5. sensitiv*
6. specific*
7. “likelihood ratio*”
8. “false negative*
9. “false positive”
10. “area under curve”
11. ROC
12. AUC
13. predict*
14. detect*
15. marker*
16. screen*
17. accura*
18. “ductus venosus”
19. “nasal bone”
20. “tricuspid regurgitation”
21. “chorion* vill* sampling”
22. amniocentesis
23. ultrasound
24. inhibin*
25. “unconjugaed oestriol”
26. “unconjugated estriol”
27. afp
28. “alpha fetoprotein*”
29. alphafetoprotein*
30. “ bhcg”
31. “human chorionic gonadotrophin”
32. “papp a”
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33. “pregnancy associated plasma protein”
34. “nuchal translucency”
35. foetal
36. fetal
37. foetus
38. foetal
39. prenatal*
40. antenatal*
41. pregnan*
42. maternal*
43. “trisomy 21”
44. mosaicism
45. “down* syndrome”
The search then used the history function to combine terms:
1-34 - combine using OR
35 - 42 - combine using OR
43 - 45 - combine using OR
The three sets were combined using AND
The combined search strategy had the form
(((((((al: “trisomy 21”) or (al: (mosaicism))) or (al: “down* syndrome”))) and (((((((((((((((((((((((((((((((((((al: “reference stan-
dard*”) or (al: “reference value*”)) or (al: “reproducibility of results”)) or (al: (diagnos*))) or (al: (specific*))) or (al: (sensitiv*)))
or (al: “likelihood ratio*”)) or (al: “false negative*”)) or (al: “false positive*”)) or (al: “area under curve”)) or (al: (auc))) or (al:
(roc))) or (al: (predict*))) or (al: (accura*))) or (al: (detect*))) or (al: (screen*))) or (al: (marker*))) or (al: “ductus venosus”))
or (al: “tricuspid regurgitation”)) or (al: “nasal bone”)) or (al: “chorion* vill* sampling”)) or (al: (amniocentesis))) or (al:
(ultrasound))) or (al: (inhibin*))) or (al: “unconjugated oestriol”)) or (al: “unconjugated estriol”)) or (al: (afp))) or (al: “alpha
feto protein*”)) or (al: “alpha fetoprotein*”)) or (al: “b hcg”)) or (al: “human chorionic gonadotropin”)) or (al: “papp a”))
or (al: “pregnancy associated plasma protein”)) or (al: “nuchal translucency”)))) and (((((((((al: (foetal)) or (al: (fetal))) or (al:
(foetus))) or (al: (fetus))) or (al: (pregnan*))) or (al: (trimester*))) or (al: (prenatal*))) or (al: (antenatal*))))))
C O N T R I B U T I O N S O F A U T H O R S
KA undertook the searches, applied eligibility criteria, extracted and entered data and wrote the first and second draft of the review.
ZA applied eligibility criteria, provided senior clinical input, oversaw the review process, and approved the final draft of the review.
JD supervised and planned the review, checked data extraction, supervised statistical analyses and wrote the second draft of the review.
JP applied eligibility criteria, provided senior clinical input, oversaw the review process, and approved the final draft of the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol intended to investigate several additional outcomes downstream from test accuracy, should they be reported in the test
accuracy studies. When we attempted to extract this information however, it was found to be available in very few studies. Where
such information was found, it was difficult to extract meaningful data to allow for comparison between studies because data were not
reported in a universal manner. In several studies such outcomes were estimated rather than measured. Often they were not reported
at all. The outcomes stated in the protocol which have not been included are: harms of testing; need for further testing; side effects
of tests; interventions and side effects; other abnormalities detected by testing; spontaneous miscarriage; miscarriage subsequent to
invasive procedure, with or without normal karyotype; fetal karyotype; termination of pregnancy (prior to definitive testing or in
a karyotypically normal pregnancy and following confirmation of Down’s syndrome or following detection of other chromosomal
abnormalities); stillbirth; livebirth of affected and unaffected fetus; uptake of definitive testing by women.
The following refinements to the eligibility criteria were imposed to ensure that the quality of the included literature remained high.
We excluded studies that identified fewer than five Down’s syndrome pregnancies in their study population. We excluded studies that
had less than 80% follow- up of participants.
In addition, the analytical strategy was informed by the volume of tests and studies included, so that we focused on key tests and test
combinations by a) only meta-analysing tests that were included in four or more studies, or b) showed more than 70% sensitivity
with at least a 95% specificity. In addition, a requirement that a minimum of 10 studies for a single test was required before subgroup
analysis was undertaken. Consequently several possible sources of heterogeneity were not investigated due to lack of data.
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N O T E S
This review belongs to a suite of planned systematic diagnostic test reviews examining antenatal screening for Down’s syndrome which
include four other titles: First trimester serum tests for Down’s syndrome screening; Second trimester serum tests for Down’s syndrome screening
(Alldred 2012); First trimester serum and ultrasound tests for Down’s syndrome screening; and First and second trimester serum tests with
and without first trimester ultrasound tests for Down’s syndrome screening. The plans for these reviews were described in a generic protocol
(Alldred 2010) published in the Cochrane Library in 2010. The project as a whole has been much larger than initially anticipated,
both in terms of size and statistical complexity. The initial search was completed in 2007 and an updated search in August 2011. After
identifying studies appropriate for inclusion, a significant amount of time has been devoted to data management and analysis.
The authors are conscious of the time lag from the latest literature search to publication, and the potential for the introduction of new
urine tests in this time frame. The authors are also conscious of the potential for publication of new data pertaining to tests included in
this review. Whilst not fulfilling the usual Cochrane up-to-date criteria, this review is published because it provides historical context
in what is a rapidly-changing field, and because it is unlikely to ever be repeated.
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